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The main objective of this proposal was to investigate the effect of vitamin B6 on colon 
carcinogenesis in vivo. Two in vivo studies were conducted to determine the role of vitamin 
B6 as a biological modifier of colon carcinogenesis. It is hypothesized that vitamin B6 may 
serve as an antioxidant in vivo and will modulate colon carcinogenesis. In the first study, a 
2X3 factorial experimental design was used to determine if three different levels of vitamin 
B6, classified as low, normal and high in conjunction with two different levels of protein 
intake, classified as normal or high, will affect post-initiation stages of colon carcinogenesis, 
in Sprague-Dawley rats. Male Sprague-Dawley male were injected with azoxymethane for 
two weeks (15mg/kg/week) and then one week later thy were allocated to different dietary 
treatment groups. After eight weeks, the effects of dietary treatment on hematological status, 
oxidative stress markers and antioxidant enzymes, as well as enumeration of preneoplastic 
lesions, aberrant crypt foci (ACF), were evaluated. The lowest level of vitamin B6 intake 
with a high protein diet reduced the growth and development of ACF. Vitamin B6 had no 
significant effect on the oxidative stress markers.  The level of protein was an important 
variable in modulating the levels of 3-nitrotyrosine and 8-OH-DG which were lower in high 
protein groups than normal protein counterparts.  
 
The objective of the second study was to investigate if a supraphysiological (5 fold higher 
than normal level) dosage of vitamin B6 could have an antioxidant effect in a metabolically 
compromised state like obesity and thereby lower th risk of colon cancer. Female Zucker 
obese (Zk-OB) rats received normal (Zk-OBN, 7 mg/kg) or high (Zk-OBH, 35 mg/kg) 
vitamin B6 (Pyridoxine-HCl) diets two weeks prior to, during and six weeks following 
injection with colon carcinogen AOM. The effects ofsupplemental vitamin B6 on 
hematological status, oxidative stress markers and tioxidant enzymes, as well as 
enumeration of ACF were carried out.  High intake of vitamin B6 significantly lowered liver 
weights and plasma cholesterol compared to the normal intake (p≤0.05). Zk-OBH rats had 
significantly reduced number of ACF compared to Zk-OBN (p≤0.05). Hepatic GSH 
increased in the ZK-OBH group with a concomitant decrease in GPx activity.  The findings 
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demonstrate that in Zucker Obese rats, a high B6 intake augmented the antioxidant potential 
and decreased sensitivity to colon carcinogenesis. These findings suggest that high vitamin 
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Colorectal cancer is a significant cause of death in the Western world. Epidemiological 
evidence indicates that nutrition plays a role in the modulation of colon carcinogenesis. In 
cancer prevention, it is important to understand which nutrients can have a protective 
effect and at which stages of pathogenesis. Epidemiological and experimental studies 
have alluded to the possibility that vitamin B6 could reduce the risk of developing colon 
cancer. 
 
Vitamin B6, also known as pyridoxine, is a co-factor for nearly 100 enzymes. Pyridoxine 
is vital to cell function by being involved in amino acid metabolism including sulphur-
containing amino acids. Vitamin B6 has also been implicated in modulating lipid 
metabolism, downregulating steroid hormone receptors, serving to alleviate oxygen-free 
radicals and more recently, functioning as an antioxidant scavenger itself. Any of the 
described functions could easily be implicated in the carcinogenic process.   
  
A limited amount of in vivo work has been conducted to determine the role of pyridoxine 
in carcinogenesis. What is not clear from the published work is if vitamin B6 deficiency 
or low intake augments the risk of developing colon ca cer. And, how does high intake 
of pyridoxine affect carcinogenesis?  Moreover, oxidative cellular damage has been 
suggested to play a role in the development of colon cancer. It needs to be determined if a 
pharmacologic dose of pyridoxine is essential for its function as an antioxidant.  
 
The ambiguities related to the biological role of vitamin B6 were addressed in two 
studies. The primary objective of the research documented in this thesis was to “further 




The specific aims were to: 
 
1. Investigate if low vitamin B6 status augments colon carcinogenesis in Sprague-
Dawley rats (Study 1). 
2. Determine if a supraphysiological dose of vitamin B6 will ameliorate the 
heightened risk of colon cancer in Zucker Obese rats (Study 2). 
 
Hypothesis: Low vitamin B6 intake will augment the risk of developing colon can er in 
part by increasing oxidative stress in vivo. 
 
To put this thesis in perspective, brief background information related to the biological 




Colon Cancer and the Potential of Vitamin B 6 as a Nutraceutical 
1.1 Colon Carcinogenesis 
Colorectal cancer is a significant cause of death in the Western world (Lipkin et. al., 
1999). It may develop sporadically, induced by dietary or environmental agents, or as a 
result of inherited cancer-predisposition syndromes, familial polyposis (FAP) and 
hereditary non-polyposis colorectal cancer (HNPCC) (Guanti and Bukvic, 2000). Colon 
cancer arises from a series of histopathologic and molecular changes that transform 
normal colonic epithelial cells into aberrant crypt foci, followed by adenomatous polyps 
and finally carcinoma (Janne and Mayer, 2000). In 1988, Vogelstein and others published 
a report that describes the accumulation of genetic events which include mutations to 
proto-oncogenes and tumor suppressor genes that occur during neoplastic progression 
(Figure 1) (Vogelstein et. al., 1988). These changes add a proliferative advantage to the 
colonic epithelial cells lining the lumen, contributing to the development of the malignant 




Figure 2. Vogelstein model of carcinogenesis 
Progression of colon carcinogenesis from normal epith lium to carcinoma. 
Morphological changes correspond to sequential genetic alterations as proposed by 




1.1.1 Aberrant Crypt Foci (ACF) 
 
Aberrant crypt foci were first described in 1987 by Bird in carcinogen-treated mice (Bird, 
1987). ACF is an accepted and relevant model in the study of the progression of 
neoplastic transformation in colonic epithelial cells. Genetic alterations including K-ras, 
APC and p53 mutations, which are a trademark of colon cancer, have been identified in 
ACF, supporting their role as preneoplastic markers (Smith et. al., 1994 and Pretlow et. 
al., 1993). As biomarkers for colon carcinogenesis, enumeration of ACF permits rapid 
and inexpensive analysis of the affect of preventative agents in disease progression.  
 
ACF are observed under the microscope once the colon mucosal surface has been stained 
with indigo carmine or methylene blue (McLellan, 199 ).  Compared to normal crypts, 
ACF appear raised from the surrounding mucosa with a t icker epithelial lining and oval 
or slit-like lumens (McLellan, 1991). They are visualized singly or grouped. Crypt 
multiplicity is an important parameter for evaluating ACF progression. ACF can be 
categorized as primal (1-3 crypts), intermediate (4-6 crypts) or advanced (7+ crypts) 
(Figure 2). Studies indicate that ACF density increases from the proximal colon toward 
the distal end which is line with the location of clorectal cancer (Roncucci et. al., 1993). 
 
ACF can be induced experimentally in the rat colon with subcutaneous administration of 
azoxymethane, a colon-specific carcinogen. The appearance of ACF is visualized 















Primal ACF  
(1-3 Crypts) 
Intermediate ACF  
(4-6 Crypts) 




1.2 Colon Cancer and Obesity 
 
There is mounting epidemiological evidence that suggests obesity is associated with 
colon cancer (Gunter and Leitzmann, 2006). Obesity i  characterized by a state of insulin 
resistance which is defined as the impaired ability of a cell to respond to insulin secreted 
for normalizing plasma glucose levels (Leonard et. al., 2005). Insulin resistance generally 
results in hyperglycemia, a condition that leads to diabetes, and has been implicated as a 
key factor in the development of colon cancer (Gunter and Leitzmann, 2006). Obesity is 
also characterized as a proinflammatory state believed to be induced by excessive 
production of storage lipids and high-circulating levels of glucose. Due to the individual 
relationships of obesity and chronic inflammation with colorectal cancer, and the role of 
obesity in causing inflammation, it is hypothesized that inflammation in obesity may be a 
key promoter of colorectal carcinogenesis (Gunter and Leitzmann, 2006). 
 
In animals, the relationship between colon cancer and obesity can be investigated using 
Zucker Obese rats (Zk-Ob) and their lean counterparts (Zk-Ln). Zucker Obese rats inherit 
obesity as an autosomal Mendelian recessive trait for the leptin receptor (fa/fa, 
homozygous for nonfunctional receptors) (Bray, 1977).  Leptin is a protein hormone that 
is secreted from adipocytes and circulates in the plasma (Pellymounter et. al., 1995). 
Leptin functions to regulate feeding and energy expenditure by sending signals to the 
hypothalamus to suppress appetite (Pellymounter et. al., 1995). As a result of the leptin 
receptor mutation, Zucker Obese rats have increased food consumption, 
hyperinsulinemia, enlarged fat cells and altered function of the endocrine system (Bray, 
1977). 
 
The physiological state of Zucker Obese rats provides an excellent model for 
investigating the role of vitamin B6 in modulating oxidative stress and colon 
carcinogenesis and its potential as a therapeutic compound in carcinogenesis. 
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1.3 Vitamin B 6 and Colon Cancer 
 
There is a significant amount of experimental evidence suggesting that dietary factors 
play an important role in the modulation of colorectal cancer (Lipkin, 1999). 
Epidemiological studies indicate an inverse relationship between vitamin B6 intake, 
plasma PLP and the risk of colon cancer. A nested case- ontrol study reported a 
statistically significant inverse association between plasma PLP concentrations and the 
risk of both colorectal and colon cancer (Wei et. al., 2005).   
 
Several in vitro studies have shown that high levels of vitamin B6 can suppress the 
growth of cancer cells (Disorbo and Litwack 1982 and Disorbo and Nathanson, 1983). 
More recently, animal models have been employed to investigate the chemopreventative 
capabilities of vitamin B6 on the development of tumors. Komatsu et al. examined the 
effect of vitamin B6 supplementation in the form of pyridoxine hydrochloride (PN HCl) 
in mice receiving azoxymethane injections over ten w eks (Komatsu et. al., 2001). Mice 
were terminated after 22 weeks. They compared the effect of 1, 7, 14 and 35 mg PN 
HCl/kg on the incidence and number of colonic tumors, cellular proliferation and 
apoptosis. Mice receiving 1 mg PN HCl/kg had a significantly higher number of 
adenomas. The number of adenocarcinomas in mice receiving 1 and 7 PN HCl/kg was 
four and three, respectively. Animals receiving 14 and 25 mg PN HCl/kg did not develop 
adenocarcinomas (Komatsu et. al., 2001). The minimum amount of pyridoxine required 
to suppress cellular proliferation was 7 mg PN HCl/kg. Cellular proliferation in the 
proximal colon was significantly lower for animals receiving 14 and 35 mg PN HCl/kg 
but did not differ among the three supplemented groups in the distal colon (Komatsu et. 
al., 2001). Supplemental vitamin B6 was shown to have no effect on apoptosis in colonic 




1.4 Role of Oxidative Stress in Carcinogenesis 
 
Oxidative cellular damage plays a significant role in the development of several human 
diseases including atherosclerosis, cancer and diabetes (Weisel, 2006).  Respiration and 
glucose metabolism generate hydroxyl radicals and other reactive species that can cause a 
wide range of oxidative damage within the cell. Reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) include super oxide anion, hydrogen peroxide and nitric 
oxide. The reaction of ROS and RNS with DNA can have deleterious effects by 
introducing single- or double-stranded breaks, modifying purine and pyrimidine bases, or 
by creating DNA cross-links (Klaunig and Kamendulis, 2004). These types of DNA 
damage can lead to changes in transcriptional activation, induction of signal transduction 
pathways, replication errors and genomic instability (Klaunig and Kamendulis, 2004). All 
of these factors are implicated in carcinogenesis. Additionally, reactive oxygen species 
can also cause damage by lipid peroxidation, which involves the loss of electrons from 
the double bonds of polyunsaturated fatty acids. Since the cell membrane is heavily 
concentrated with polyunsaturated fatty acids, lipid peroxidation alters membrane 
integrity (Thomas et. al., 1995).  
 
Non-enzymatic antioxidants and antioxidant enzymes function to counteract the effect of 
reactive oxygen species forming an antioxidant network (Figure 3). Since antioxidants 
interact with and regenerate other antioxidants within he network, a reduction of one of 
these species can have a significant effect on the balance and function of the system. The 
most effective antioxidant enzymes include superoxide dismutase (SOD), catalase and 
glutathione peroxidase (GPx). Superoxide dismutase is a metalloprotein that dismutes 
superoxide anion (O2-) forming hydrogen peroxide (H2O2) (Valko et. al., 2006). Catalase 
and glutathione peroxidase compete for H2O2 as a substrate in a decomposition reaction 
that yields water, thereby protecting the cell against oxidative damage. Non-enzymatic 
antioxidants include Vitamin C, Vitamin E, carotenoids, thiol antioxidants (glutathione, 
thioredoxin and lipoic acid), and flavanoids (Valko et. al., 2006).  
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The non-enzymatic antioxidant, glutathione, is a tripeptide and a major soluble thiol-
disulphide redox buffer of the cell (Thomas et. al., 1995). It is highly abundant in the 
cytosol, nuclei and mitochondria (Thomas et. al., 1995). The reduced form of glutathione is 
GSH and the oxidized form is referred to as glutathione disulphide (GSSG). GSH has many 
protective roles including scavenging hydroxyl radic ls and singlet oxygen directly and 
serving as a co-factor for glutathione peroxidase (Valko et. al., 2006). The antioxidant 
capacity of GSH is due to the sulphur compound thatcan accommodate the loss of an 
electron. It can also regenerate many important antioxidants to their active forms: Vitamin 
C and E (Valko et al., 2006). Due to GSH’s role in reducing oxidized products and 
regenerating other antioxidants, the ratio of GSH/GSS  is a good measure of oxidative 









1.5 Physiological Role of Vitamin B 6  
 
Vitamin B6 is a water-soluble vitamin required for normal growth and development. It 
exists in three free forms which include pyridoxine (PN), pyridoxal (PL), and 
pyridoxamine. Each form can be converted to the active coenzymes, pyridoxal 5’-
phosphate (PLP) and pyridoxamine 5’-phosphate (PMP), by phosphorylation at the 5’ 
position in the liver (Leklem, 1999). The PLP form is covalently bound to enzymes via a 
Schiff base with the ε-amino group of lysine. Vitamin B6 has many important functions 
that are complex and interrelated. Due to the reactivity of PLP with amino acids and 
nitrogen containing compounds, amino acid metabolism is the most recognized function 
(Leklem, 1988). PLP is also involved in gluconeogenesis, niacin formation, lipid 
metabolism, steroid hormone modulation, homocysteine conversion, and red blood cell 
metabolism and function. Additionally, both the nervous and immune systems require 
vitamin B6 to function efficiently. 
 
1.5.1 Relationship between Protein Intake and B 6 Requirement 
 
The recommended daily intake for vitamin B6 in adult males and females under the age 
of 50 is 1.3 mg/d (Food and Nutrition Board, 2005). Due to its broad role as a co-factor in 
many metabolic processes, adequate consumption is necessary. The requirement for 
vitamin B6 is related to the level of dietary protein; high protein intake increases B6 
requirement (Okada et. al., 1998). PLP functions as a co-enzyme for transaminases that 
participate in the catabolism of all amino acids (Okada, 1971). These include 
transaminases L-alanine and L-aspartate. During high protein intake, the activities of 
liver transaminases are generally induced to compensat  for increased catabolism of 
amino acids (Okada, 1971). However, in a vitamin B6 deficient state, rats receiving high 
protein (70% casein) have significantly decreased activities of these hepatic 
transaminases (Okada, 1971). The animals have also been shown to develop fatty livers 
with increased levels of glycerides and cholesterol. Growth inhibition is also observed 




Studies indicate that when vitamin B6 intake is adequate, high dietary protein favors 
retention of the vitamin in the liver. Conversely, during deficient intake of vitamin B6, 
liver levels of PLP are inversely proportional to pr tein intake (Itoh and Okada, 1973 and 
Okada et. al., 1998).   A study of men receiving adequate amounts of vitamin B6 (1.6 mg) 
has shown that plasma concentrations of PLP and urinary 4-pyridoxic acid are also 
inversely related to protein intake (Miller, 1985). Okada et. al. also showed that the 
plasma B6 levels of rats fed a 20% casein diet were higher than t at of groups receiving 
70% casein when there was an equal amount of B6 in the diets (Okada, 1998).  
 
1.5.2 Glutathione Production: Role of Vitamin B 6 in Homocysteine Metabolism 
 
Homocysteine is a non-protein forming sulfur amino acid. Hyperhomocysteinemia is a 
condition that refers to elevated levels of homocysteine in the plasma and most notably 
leads to vascular disease. Levels of plasma homocysteine and its metabolism are 
influenced by genetic and dietary factors including methionine content and circulating 
folic acid, vitamin B12 and vitamin B6 (Selhub, 1999). Homocysteine can be metabolized 
by one of two pathways: remethylation or transulfuration (Figure 4). Remethylation 
involves converting homocysteine to methionine, a re ction that is B12-dependent in all 
tissues (Selhub, 1999). Transulfuration involves metabolizing homocysteine to cysteine 
by two PLP-dependent enzymes: cystathionine β-synthase (CBS) and cystathionine γ-
lyase (CGS). Cysteine is an essential amino acid and the limiting reagent for glutathione 
synthesis (Davis et. al., 2005). CBS irreversibly catalyzes the condensation of 
homocysteine with serine to form cystathionine. Cystathionine is then converted to 
cysteine by CGS (Davis et. al., 2005).  
 
Previous studies have reported that vitamin B6 deficiency causes elevated levels of 
homocysteine in tissue and plasma. Other observed eff cts of vitamin B6 deficiency 
include increased lipid peroxidation in plasma, kidney, heart, and liver tissues, and 
decreased activity of PLP-dependent CBS (Ravichandran and Selvam, 1990 and Cabrini 
et. al., 1998 and Cabrini et. al., 2005). In another study, vitamin B6 deficiency resulted in 
decreased activity of CGS. Male Wistar rats consuming diets high in protein (70% 
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casein) and deficient in vitamin B6 excreted unusually high amounts of cystathionine 
which appeared to be reflective of decreased cystathionine γ-lyase activity (Okada, 
1974). Rats receiving high-protein diets with pyridoxine supplementation only had traces 
of the amino acid. Cumulatively, the results of previous studies suggest that vitamin B6 
deficiency should reduce glutathione synthesis as evidenced through elevated levels of 
homocysteine and decreased activities of CBS and CGS. As a result, reduced glutathione 





The black arrow indicates remethylation while the green arrow indicates the 
transulfuration pathway. Methionine is converted to S-adenosyl-methionine (SAM), the 
main methyl donor in the body. SAM can be further converted to S-adenosyl-
homocysteine (SAH) and then to homocysteine. Homocysteine metabolism to cysteine is 
catalyzed by two PLP-dependent enzymes: CBS and CGS. Additional Abbreviations: 
THF, tetrahydrofolate; MethylTHF, N-5-Methyltetrahydrofolate; MethyleneTHF, N-5-
Methylenetetrahydrofolate. Adapted from Selhub 1999. 

























    
1.5.3 Role of Vitamin B 6 as a Modulator of Oxidative Stress 
 
Dietary factors play a role in both promoting and preventing oxidative stress (Thomas, 
1994). As described earlier, vitamin B6 functions as a co-factor in glutathione synthesis 
thereby serving as a modulator of oxidative stress. More recently, vitamin B6 has been 
proposed to have antioxidant properties by functioning as a scavenger for free radicals 
(Grimble 1997 and Kannan and Jain, 2004).  
 
In 2004, Kannan and Jain proposed through a study using U937 monocytes cultured with 
PN and PLP, that vitamin B6 might function as an antioxidant by scavenging oxygen 
radicals. Treatment of the U937 cell line with vitamin B6 showed that higher 
concentrations significantly decreased the generation of ROS, lipid peroxidation, and 
H2O2-induced changes in mitochondrial membrane permeability (Kannan and Jain, 
2004).  Evidence suggests that phenolic compounds react faster with peroxy radicals than 
peroxy radicals can react with the lipids (Noguchi et. al., 1998). Studies indicate that 
functional groups such as hydroxyl and amine can also scavenge oxygen radicals 
(Noguchi et. al., 1998). Given the chemical structure of vitamin B6 as a phenolic 
compound with both hydroxyl and amine groups substituted on the pyridine ring, Kannan 
and Jain hypothesized that, alone, it can function as an antioxidant. However, the exact 
chemical mechanism by which pyridoxine would scavenge oxygen radicals and inhibit 
lipid peroxidation has not yet been confirmed. 
 
A physiological difference may exist between adequate consumption of vitamin B6, which 
ensures a balance in the antioxidant network, and supplementary intake to quench 
excessive production of reactive oxygen species. The cellular concentration of 
glutathione has a major affect on the balance of the antioxidant network. Consequently, it 
should be expected that compromised vitamin B6 status, the result of reduced intake, will 
lead to decreased glutathione allowing reactive oxygen species to accumulate, translating 
to cancer promoting effects. In an obese state chara terized by hyperglycemia, adequate 
consumption of vitamin B6 may not be enough to counteract the physiological 
consequences of high glucose. In diabetic patients a d in vitro studies, high levels of 
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glucose have been shown to generate superoxide radicals from the autoxidation of 
glucose, resulting in increased cellular lipid peroxidation and glycosylated hemoglobin 
(Jain and Lim, 2001). In the proposed role of an oxygen radical scavenger, supplementary 
vitamin B6 may be necessary to normalize levels of ROS and enhance glutathione 
production and, in doing so, exert a protective effct against colon carcinogenesis.      
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Chapter 2  
Materials and Methods 
 
2.1 Materials 
Unless otherwise stated all chemicals and reagents were purchased from Sigma Chemical 
Co., Mississauga, Ontario. 
2.2 Animal Care 
Sprague Dawley, Zucker Obese and Lean rats were procured from Charles River Canada 
(St-Constant, Quebec). Animals were housed in polypr pylene cages lined with 
woodchip bedding and stainless steel wire mesh lidsin the Animal Facility. 
Environmental conditions were controlled for temperatu e and humidity and maintained 
at 24°C and 55%, respectively, with a 12 hour light/dark photoperiod. Animals were 
housed in groups of three or four and given access to diet and water ad libitum. Animal 
care and all investigative procedures adhered to guidelines of the Office of Research 
Ethics, University of Waterloo (AUPP:04-17) and theCanadian Council of Animal Care.  
2.3 Diets 
All experimental diets (Harlan Teklad, Madison, WI) were based on the semi-synthetic 
AIN-93G diet containing 5% corn oil (wt/wt). In Study 1, diets were modified with 
respect to casein and pyridoxine hydrochloride (PN-HCl) (Appendix B, Table 1). In 
Study 2, diets were modified with respect to PN-HCl only (Appendix B, Table 2). 
2.4 Complete Blood Count 
At termination, a sample of blood from each animal w s collected in a EDTA vacutainer 
tube (BD Vacutainer Systems, NJ) from a cardiac puncture using multiple sample Luer 
adapter and sent to Animal Health Laboratories (University of Guelph, Guelph, ON) for 
complete blood count. The complete blood count (CBC) was performed using the Adiva 
120 Hematology System. 
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2.5 Biochemical Assessment 
A sample of blood from each animal was collected in a heparinized vacutainer tube (BD 
Vacutainer Systems, NJ) from a cardiac puncture using a multiple sample Luer adapter 
and centrifuged for 10 min at 2000 rpm to separate plasma. Plasma samples were 
aliquoted and sent to Animal Health Laboratories (University of Guelph, Guelph, ON) for 
biochemical analysis using rat specific parameters. 
2.5.1 Creatinine 
Serum creatinine concentration is an accepted index for glomerular filtration rate and is 
used to assess renal function (Perrone et. al., 1992). Creatinine was measured using an 
enzymatic ultraviolet absorbance method. Creatinine s hydrolyzed by creatinine 
deiminase to ammonia and N-methylhydantoin (Fossati et. al., 1994). The ammonia 
produced combines with 2-oxoglutarate and NADPH in the presence of glutamate 
dehydrogenase (GLDH) to yield glutamate and NADP+ (Fossati et. al., 1994). The 
reduction in absorbance at 340 nm caused by the oxidation of NADPH between two fixed 
time points is proportional to the amount of creatinine in the sample. Prior to the addition 
of creatinine deiminase, endogenous ammonia present in the sample is removed by the 
addition of GLDH. 
 
2.5.2 Urea 
Plasma urea was determined using a commercially available kinetic UV assay kit from 
Roche. Urea analysis is based on the enzymatic determination method described by Talke 
and Schubert (1965) that uses the coupled urease/glutamate dehydrogenase (GLDH) 
enzyme system. Urea is the final degradation product of protein and amino acid 
metabolism. In this experiment, urea is hydrolyzed by urease to form CO2 and ammonia. 
The ammonia formed then reacts with α-ketoglutarate and NADH in the presence of 
glutatmate dyhydrogenase (GLDH) to yield glutamate nd NAD+. The decrease in 




2.5.3 High Density Lipoprotein-Cholesterol (HDL-C) 
Plasma HDL-C was determined using a direct enzymatic colorimetric test from Roche. 
The automated method for direct determination uses polyethylene glycol (PEG)-modified 
enzymes and dextran sulfate. In the presence of magnesium sulfate, dextran sulfate 
selectively forms water-soluble complexes with low density lipoproteins (LDL), very low 
density lipoproteins (VLDL) and chylomicrons which are resistant to PEG-modified 
enzymes. Cholesterol esterase and cholesterol oxidase enzymes are coupled with PEG 
which results in selective catalytic activities toward lipoprotein fractions, with increasing 
reactivity in the order of HDL>VLDL and chylomicrons>LDL. Following the addition of 
PEG-modified enzymes and 4-amino-antipyrine in buffer, HDL-cholesterol esters are 
hydrolyzed by PEG-cholesterol esterase to form HDL-cholesterol and fatty acids. In the 
presence of oxygen, cholesterol is oxidized by cholesterol oxidase to its corresponding 
ketone and hydrogen peroxide (H2O2). In the presence of peroxidase, H2O2 reacts with 4-
amino-antipyrine and HSDA to form a purple dye. The int nsity of the dye was directly 
proportional to the cholesterol concentration and was measured photometrically. 
 
2.5.4 Cholesterol 
Plasma cholesterol was determined using a commercially available enzymatic 
colorimetric test supplied by Roche (CHOD-PAP). In this enzymatic assay, cholesterol 
esters are hydrolyzed by cholesterol esterase (CE) to cholesterol, which is then oxidized 
by cholesterol oxidase (CO) to yield cholest-4-en-3-one and H2O2 co-products. The 
concentration of cholesterol is detected through the amount of H2O2 formed. Peroxidase 
catalyzes the oxidative coupling of phenol with 4-aminophenazone which reacts with 
H2O2 to give a red coloured quinone-imine. This is based on the Trinder (1969) reaction. 




Plasma glucose was determined using an enzymatic colorimetric assay from Roche. In 
this experiment, glucose is oxidized by glucose oxidase (GOD) to gluconolactone in the 
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presence of atmospheric oxygen. Measurement of the amount of H2O2 produced is 
through the Trinder (1969) reaction. The hydrolysis of H2O2 by peroxidase is detected 
using phenol and the chromogen 4-aminophenazone which acts as an oxygen receptor, 
producing a red colored compound known as 4-(p-benzoquinone-monoinino)-phenazone. 
The optical density was measured at 505 nm using a spectrophotometer to give the 
concentration of glucose. 
 
2.5.6 Triglycerides  
The level of plasma triglycerides was determined using a commercially available 
colorimetric enzyme kit from Roche (GPO-PAP). In this experiment, lipoprotein lipase 
from microorganisms is used to hydrolyze triglycerid s to glycerol. Glycerol kinase (GK) 
then phosphorylates glycerol forming glycerol-3-phosphate. Glycerol-3-phosphate is 
oxidized to dihydroxyacetone phosphate and H2O2. The H2O2 reacts with 4-
aminophenazone and 4-cholorophenol under the catalytic ction of peroxidase to form a 
red dye, 4-(p-benzoquinon-monoimino)-phenazone. The intensity of dye was measured 
using Roche clinical chemistry analyzers. 
 
2.5.7 Total Bilirubin 
Measurement of bilirubin is used to detect liver disease, hemolytic anemia and to 
evaluate the degree of jaundice. Total bilirubin in plasma was quantitatively determined 
using the Roche automated clinical chemistry analyzer. Plasma samples are mixed with a 
reagent that contains sodium acetate buffer, sulfamic acid, a surfactant and solubilizer. 
The surfactant is added to accelerate the reaction and avoid protein precipitation. Under 
strongly acidic conditions (pH 1-2), total bilirubin s rapidly coupled with a diazonium 
ion that is later added to the mixture, forming azobilirubin. The intensity of the color 
from azobilirubin was measured photometrically and was proportional to the 




2.5.8 Aspartate Aminotransferase (AST) Analysis 
AST activity in plasma is determined using the Roche automated clinical chemistry 
analyzer. In this experiment, AST catalyzed the reaction between α-ketoglutarate and L-
aspartate, forming L-glutamate and oxaloacetate. The increase in oxaloacetate was 
determined in an indicator reaction catalyzed by malate dehydrogenase (MDH) where 
NADH was oxidized to NAD+. The rate of NADH oxidation was photometrically 
determined and was directly proportional to the rat of formation of oxaloacetate, thereby 
indirectly giving AST activity.  
 
2.5.9 Alanine Aminotransferase (ALT) Analysis 
Determination of ALT activity was performed according to a standardized method 
recommended by the International Federation of Clinical Chemistry using a Roche 
automated clinical chemistry analyzer. To prevent competing reactions with NADH, 
plasma samples were pre-incubated with a TRIS buffer that contains L-alanine, NADH 
and lactate dehydrogenase (LDH). In this experiment, ALT catalyzed the reaction 
between α-ketoglutarate and L-alanine. The pyruvate that was produced from this 
reaction was subsequently measured in an indicator reaction which was catalyzed by 
LDH. In the indicator reaction, NADH was oxidized to NAD+. The rate of decrease in 
NADH was photometrically measured and was directly proportional to the rate of 
production of pyruvate and thereby giving the rate of ALT activity. 
 
2.5.10 Creatine Kinase (CK) 
CK activity was measured using the method proposed by Szasz (1979) and was 
quantitatively determined using a Roche automated clinical analyzer. CK was rapidly 
inactivated by oxidation of sulfhydryl groups in the active center. N-acetylcysteine 
(NAC) was added to reactivate the enzyme. Diadenosine pentaphosphate (ATP) and 
AMP were added to prevent interference by adenylate kinase. CK catalyzes the 
phosphorylation of ADP in the presence of creatine phosphate, to form adenosine 
triphosphate (ATP) and creatine. Hexokinase (HK) in the presence of magnesium ions 
catalyzed the phosphorylation of glucose by the ATP formed to produce glucose-6-
phosphate. Glucose-6-phosphate dehydrogenase oxidized glucose-6-phosphate with 
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simultaneous reduction of the coenzyme nicotinamide a nine dinucleotide phosphate 
(NADP) to give NADPH and 6-phosphogluconate. The rat  of NADPH formation was 
measured at 340 nm and was directly proportional to the activity of CK in the sample. 
 
2.5.11 Total Protein 
Total protein in plasma was analyzed using a colorimetric assay kit available from Roche. 
Plasma samples were mixed with copper in an alkaline solution. Divalent copper reacted 
with protein peptide bonds to form a purple coloured biuret complex. The color intensity 
was directly proportional to the protein concentration which was determined 
photometrically using a Roche automated clinical chemistry analyzer. 
 
2.5.12 Albumin 
The concentration of plasma albumin was colorimetrically determined using an endpoint 
method and quantified using a Roche automated clinica  chemistry analyzer. Plasma 
samples were treated with a citrate buffer containing bromocresol green (BCG). At a 
pH=4.1, albumin displays a cationic character that enables it to bind with bromocresol 
green (BCG) to form a blue-green complex. The change in absorbance at 628 nm 
correlates with the concentration of albumin.  
 
2.6 Pyridoxal 5’-Phosphate Measurement 
The concentration of plasma PLP was determined within the laboratory of Dr. Jim House 
at the University of Manitoba. Plasma PLP concentrations were quantitatively determined 
using a commercially available radioenzymatic assay kit (ALPCO, Windham, NH, 
Vitamin B6 PLP 
3H-REA). Due to the sensitivity of PLP to light, measurement was 
performed under protection from direct light exposure. The kit follows the principle that 
3H-tyrosine is decarboxylated by tyrosine apodecarboxylase (Y-apoDC), a vitamin B6 
dependent enzyme from Streptococcus faecalis. The activity of tyrosine 
apodecarboxylase is dependent on the amount of PLP present in the sample. The resulting 
compound that was produced, 3H-tyramine, was selectively extracted in a scintilla ion 
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cocktail and was measured by liquid scintillation counting. The inter- and intra-assay 
coefficients of variation were < 10% and <5%, respectiv ly. 
 
2.7 Homocysteine and Cysteine Measurement 
Measurement of plasma total homocysteine and cysteine was determined within the 
laboratory of Dr. Jim House at the University of Manitoba. Thiol measurement was 
determined using the reverse phase high performance liquid chromatography (HPLC) 
method of Araki and Sako (1987), with modifications a  suggested by Gilfix et. al. 
(1997). Plasma samples were incubated with tris-carboxyethylphosphine (TCEP; Fisher 
Scientific, Nepean, ON) to reduce protein-bound andoxidized forms of homocysteine, 
followed by derivatization with 7-fluorobenzofurazan-4-sulfonic acid ammonium salt 
(SBD-F; Sigma Chemical Co., Oakville, ON).  The fluorescent thiol derivatives were 
separated on a Waters C-18 column (5 µM, 4.5 x 250 mm; Waters Canada, Mississauga, 
ON) using isocratic elution (98% 0.1 M acetate, pH 5.5: 2% methanol) by means of a 
Shimadzu HPLC system (Man-Tech Associates, Guelph, ON) complete with autoinjector 
and fluorescence detector (excitation λ = 385 nm; emission λ = 515 nm). Concentrations 
of total homocysteine and cysteine were determined through the use of an external 
standard curve, and the inter- and intra-assay coeffi ients of variation were < 2%. 
 
2.8 Plasma 3-Nitrotyrosine and 8-OH-DG Quantificati on 
Plasma was assayed for levels free 3-nitrotyrosine and 8-hydroxy-2-deoxyguanosine (8-
OH-DG) at the Ottawa Health Research Institute (Ottawa, ON). Analyses were carried 
out via a novel, highly sensitive non-radioactive HPLC method allowing simultaneous 
measurement of multiple oxidative stress markers (Kumarathasan and Vincent, 2003). 
The analytical precision values are 95% for HPLC Coularray. 
 
2.9 Colon Preparation 
The colon from each animal was removed and flushed with ice-cold saline solution and 
placed on a cold plate set at 4°C. A longitudinal cut was made from the rectal to the 
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ceacal end. Colons intended for morphological analyses were spread flat between two 
filter papers and fixed in 10% neutral buffered formalin.  
 
In the Sprague-Dawley study, four colons in each group had a small section of mucosa 
scraped from each end (4 cm of proximal and 2 cm of distal end). The mucosa was frozen 
in liquid nitrogen and stored at -80°C for biochemical analyses.  
 
2.9.1 Aberrant Crypt Foci (ACF) Enumeration 
Enumeration of ACF was conducted according to the method described by Bird (1987). 
Fixed colons were cut into 6 cm sections and stained with 0.2% methylene blue stain for 
4 minutes. Stained sections were placed mucosal side up on a microscope slide and 
observed through a light microscope. ACF were enumerated in 2 cm sections moving 
from the proximal to caecal end. The variables used to assess the aberrant crypts were 
occurrence and multiplicity. ACF were classified as primal (1-3 crypts), intermediate (4-6 
crypts) or advanced (7+ crypts). 
 
2.10 Preparation of Whole Extract from Liver Tissue  
One gram of liver tissue stored at -80°C was sectioned and added to 3 mL of ice-cold 
RIPA buffer (50 mM Tris-HCl, 1% NP-40, 0.25% Sodium Deoxycholate, 150 mM NaCl, 
1 mM EDTA, 1 mM NaF) with freshly added protease inhibitors (1µg/mL of Aprotinin, 
Leupeptin, Trypsin Inhibitor, Sodium Orthovandate) and then homogenized in ice using 
the PT2100 Polytron homogenizer. The homogenate was centrifuged at 15,000 rpm for 
20 min at 4°C. The top lipid layer was removed and the supernatant was collected and 
aliquoted into pre-chilled eppendorf tubes and stored in -80°C for further analysis. 
 
Samples of whole extract from liver tissue were used for analysis of cholesterol, 




2.11 Liver Cholesterol Assay 
The Amplex Red Cholesterol Assay Kit (Molecular Probes, Eugene, OR) provides a 
simple fluorometric method for the sensitive measurement of cholesterol using a 
fluorescence microplate reader. In this enzymatic assay, cholesterol esters were 
hydrolyzed by cholesterol esterase (CE) into cholesterol, which was then oxidized by 
cholesterol oxidase (CO) to yield the corresponding ketone and H2O2. This enzymatic 
method for assaying cholesterol is based on the measur ment of H2O2 by way of 
horseradish peroxidase (HRP)-coupled oxidation of Amplex Red, an H2O2-sensitive 
probe. Amplex Red reagent reacted with H2O2 to produce highly fluorescent resorufin. 
 
To measure cholesterol, 50 µg of liver homogenate was analyzed with the Amplex Red 
cholesterol fluorescence assay kit according to the manufacturer’s instruction. In brief, 
the assay was conducted in a 96-well microplate using a total of 100 µl reaction volume 
per well. Reagents added to reaction mixtures included 300 µM Amplex Red, 2 U/mL 
HRP, 2 U/mL cholesterol oxidase and 0.2 U/mL cholesterol esterase. The reaction 
mixtures were incubated at 37°C for 30 mins, and the fluorescence intensities were 
measured (excitation λ = 560 ± 10 nm; emission λ = 590 ± 10 nm) to determine 
cholesterol concentration. 
2.12 Colorimetric Determination of Glutathione  
The QuantiChrom Glutathione Assay Kit (BioAssay Systems, Hayward, CA, DIGT-250) 
was used to measure reduced glutathione in plasma and hepatic tissue samples of 
Sprague-Dawley rats. The simple and direct method used 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB) to detect reduced glutathione. A reaction between DTNB and reduced 
glutathione formed a yellow product. The optical density of the yellow product measured 
spectrophotometrically at 412 nm, was proportional to sample glutathione concentration. 
 
The assay was conducted in a clear bottom 96-well plate using a final reaction volume of 
300 µl per well. The concentration of reduced glutathione in liver tissue was assayed 
using hepatic tissue samples homogenized in RIPA buffer. Equal volumes of sample 
(plasma or liver extract) and sodium tungstate/DTNB reagent were mixed in eppendorf 
tubes and centrifuged at 14,000 rpm for 5 min. The supernatant for each sample was 
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transferred into the wells in duplicates and 100 µl of phosphate buffer was added to 
stabilize the colour produced in the reaction. The reaction mixtures were incubated at 
room temperature for 25 min and the optical density was measured at 412 nm. The inter-
assay coefficient of variation was <2%. 
 
2.13 Colorimetric Determination of Nitrite (NO 2
-) 
Nitrite (NO2
-) is a stable oxidation product of nitric oxide (NO). The QuantiChromTM 
Nitric Oxide (NO) Assay kit (BioAssay Systems, Hayward, CA, DINO-250) follows the 
two step Griess method (1879) for colorimetrically determining the concentration of 
nitrite. 
 
The assay was conducted in a clear bottom 96-well plate using a final reaction volume of 
200 µl per well. Sample preparation included a two-step deproteination. In the first step, 
100 µl of hepatic tissue homogenized in RIPA buffer or plasma was mixed with 80 µl of 
75 mM ZnSO4. The mixture was centrifuged at 14,000 rpm for 5 min. The supernatant 
was then transferred to eppendorf tubes containing 120 µl 55 mM NaOH for a second 
deproteination. The mixture was centrifuged at 14,000 rpm for 5 min and the supernatant 
was mixed with glycine buffer. Reduction of NO3
- was achieved by the addition of 3 
copperized cadmium granules to each sample/glycine mixture and followed by a 15 min 
incubation period at room temperature. Duplicate volumes of each sample were 
transferred into wells.  Sulphanilic acid was added to react with NO2
-, forming a 
diazonium salt.  In a second step, 50 µl of N-(1-naphthyl)ethylenediamine was added to 
react with the diazonium ion forming a chromophoric azo. The reaction mixtures were 
incubated for 5 min at room temperature and the optical densities were measured at 540 
nm. The inter-assay coefficient of variation was <8%. 
 
2.14 Superoxide Dismutase (SOD) Assay 
 
The activity of SOD in liver tissue was assayed using a commercially available kit 
(Cayman Chemical Ann Arbor, MI, Catalog No. 706002). This kit employs tetrazolium 




2.14.1 Sample Preparation 
A 1 g section of liver tissue from each Zucker Obese and lean rat and a 0.5 g section from 
each Sprague-Dawley animal was mixed with 7 ml of cold buffer (20 mM HEPES buffer, 
pH 7.2, containing 1 mM EGTA, 210 mM mannitol and 70 mM sucrose) and 
homogenized in ice using the PT2100 Polytron homogenizer. Homogenates were 
centrifuged at 1,500 g for 5 min at 4°C. The supernata t was separated from cell debris 
and aliquoted in chilled eppendorf tubes.  The protein concentration of each sample was 




The SOD assay was conducted in a 96-well microplate using a total of 230 µl reaction 
volume per well and each sample was assayed in duplicate. Each well was loaded with 
200 µl of radical detector and 10 µl of undiluted Sprague-Dawley liver sample. In the 
Zucker Obese study, liver samples were diluted 10x with sample buffer and then mixed 
with radical detector. Reactions were initiated through the addition of 20 µl of xanthine 
oxidase to each well. The reaction mixtures were incubated on a plate shaker at room 
temperature for 20 min and the absorbance was measured at 450 nm using a plate reader. 
The intra- and inter-assay coefficients of variation were 3.2% and 3.7%, respectively. 
 
2.15 Glutathione Peroxidase (GPx) Assay 
GPx activity was assayed using a commercially availble kit (Cayman Chemical Ann 
Arbor, MI, Catalog No. 703102). The procedure was bed on the Paglia and Valentine 
method (1967) and indirectly measured GPx activity in a reaction coupled with 
glutathione reductase (GR). Upon reduction of hydrope xides by GPx, oxidized 
glutathione (GSSG) was recycled to its reduced state by GR and NADPH. The 




2.15.1 Sample Preparation 
A 1 g section of liver tissue from was mixed with 10 ml of cold buffer (50 mM Tris-HCl, 
pH 7.5, 5 mM EDTA, and 1 mM DTT) and homogenized in ice using the PT2100 
Polytron homogenizer. Homogenates were centrifuged at 10,000 g for 20 mins at 4°C. 
The supernatant was separated from cell debris and aliquoted in chilled eppendorf tubes.  
The protein concentration of each sample was determin d using the Bradford method 
(1976) and samples were stored in -80°C for the assay.  
 
2.15.2 Assay 
The assay was conducted in a 96-well microplate using a total of 190 µl reaction volume 
per well. Liver homogenate samples were diluted 10x using sample buffer (50 mM Tris-
HCl, pH 7.6, containing 5 mM EDTA and 1 mg/ml BSA). Equal volumes of 20 µl of 
liver homogenate were added to each well. To diluted sample, 100 µl of assay buffer and 
50 µl of co-substrate were added. Reactions were initiated with the addition of cumene 
hydroperoxide substrate. The reaction mixtures were shaken for a few minutes and the 
decrease in absorbance was continuously monitored sp ctrophotometrically at 340 nm for 
a period of 6 min. One unit of GPx activity was expressed as the amount of enzyme that 
would catalyze the oxidation of 1.0 nmol NADPH to NADP+ per minute at 25°C. The 
intra- and inter-assay coefficients of variation were 5.7% and 7.2%, respectively. 
 
2.16 Catalase (CAT) Activity  
Hepatic CAT activity was assayed using the commercially available Catalase Assay Kit 
(Catalog No. 707002, Cayman Chemical, Ann Arbor, MI). The procedure was performed 
according to the Johansson and Borg method (1988) which exploits the enzyme’s 
peroxidatic function in the presence of methanol. In this experiment, the substrate 
methanol functions as an electron donor for CAT, generating 2 molecules of water and 
formaldehyde. The amount of formaldehyde generated was measured 
spectrophotometrically at 540 nm by reaction with 4-amino-3-hydrazino-5-mercapto-




2.16.1 Sample Preparation 
A 0.5 g section of liver from was homogenized in 5 ml of buffer (50 mM potassium 
phosphate, pH 7.0, containing 1 mM EDTA) using the PT2100 Polytron homogenizer. 
The homogenized sample was centrifuged at 10,000 g for 15 minutes at 4°C and the 
supernatant was isolated for protein concentration and CAT activity determination.  
 
2.16.2 Assay 
Liver homogenate samples were diluted 400x in diluted sample buffer (25 mM potassium 
phosphate, pH 7.5, containing 1 mM EDTA and 0.1% BSA). To each well, 100 µl of 
diluted assay buffer, 30 µl methanol and 20 µl of sample was added. Reactions were 
initiated by the addition of 20 µl of dilute H2O2 to each mixture and incubated for 20 
mins at room temperature. Subsequently, 30 µl of potassium hydroxide was added to 
terminate the reaction and 30 µl of Purpald was added to each well. The reaction 
mixtures were incubated for 10 mins at room temperature on a shaker. Finally, 10 µl of 
potassium periodate was added to each well and the plat was incubated for 5 min at 
room temperature. The optical density of each well as read at 540 nm using a plate 
reader. The inter-assay coefficient of variation was 9.9%. 
2.17 Statistical Analysis 
Statistical analysis was carried out using SPSS 15.0 statistical software (Chicago, IL). A 
comparison between Sprague-Dawley groups was performed using two-way ANOVA in 
conjunction with LSD post-hoc analysis. Statistical analysis for Zucker Obese and Lean 
groups was conducted using a one-way ANOVA in conjunction with LSD post-hoc 
analysis. For plasma nitrite results in Study 2, statistical analysis was carried out via a 





Study 1: The Effect of Low Vitamin B 6 on Post-initiation Stages 
of Colon Carcinogenesis 
3.1 Study Background and Aims 
Epidemiological and experimental studies have implicated vitamin B6 in reducing the risk 
of colon cancer. Limited in vivo evidence is available making it is unclear if a low B6 
intake increases risk or if a high intake decreases ri k. 
 
In this study, we wanted to ensure that we investigate the effect of low B6 status on colon 
cancer. High protein intake is a popular dieting trend, particularly by those wanting to 
increase lean muscle mass. However, due to the interrelationships between protein and 
vitamin B6; high dietary protein increases the requirement for vitamin B6 resulting in 
lowered circulating levels.  Theoretically, this should translate into a reduced availability 
of vitamin B6 to the colon, leading one to ask - will high dietary protein compromise 
vitamin B6 status and cause an increase in sensitivity to coln carcinogenesis? To answer 
this question, a study was designed in Sprague-Dawley rats which consists of two 
different protein levels (normal and high), each containing three different levels of 
vitamin B6 (low, normal and high). The rational for including a high-protein group in 
combination with low B6 was to determine if vitamin B6 status was compromised and the 
implications. Because one can argue that protein itself can be an important nutrient 
affecting carcinogenesis, a 2x3 factorial design was constructed to distinguish the effect 
of vitamin B6 from that of protein. 
 
We also reasoned that if vitamin B6 functions as an antioxidant, then a reduction in the 
vitamer should result in increased levels of reactive oxygen species.  It is thought that 
higher levels of reactive oxygen species will enhance pathogenesis resulting in an 
increased number and growth of putative preneoplastic lesions, ACF. Conversely, 
supplementary vitamin B6 is thought to improve redox balance by scavenging reactive 
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oxygen species and increasing the production of GSH. Reduced ROS and RNS species 
should decrease DNA damage causing carcinogenesis and thereby reduce ACF growth. 
 
The specific aims of this study were: 
 To examine the effect of different levels of vitamin B6 associated with a normal 
and high-protein diet during post-initiation stages of colon carcinogenesis in 
Sprague-Dawley rats on the number and growth of preneoplastic lesions.  
 To determine if vitamin B6 is functioning as an antioxidant at the tissue levl.  
 
3.2 Methodological Approach 
Details of the experimental procedures are described in Chapter 2, Materials and 
Methods. Briefly, a 2X3 factorial experimental design was used to determine if three 
different levels of vitamin B6, classified as low, normal and high, would affect the 
physiological level of oxidative stress markers, and the growth and number of ACF, at 
two different levels of protein intake, classified as normal or high, in Sprague-Dawley 
rats. See Figure 5 for a detailed illustration of the experimental design. Six week-old male 
Sprague Dawley rats (n=48) were placed on standard lab chow upon arrival (Rodent Diet 
5001, Labdiet, MO, USA). Following a one-week period f acclimation to laboratory 
conditions, they were subcutaneously injected with the colon-specific carcinogen AOM 
diluted in 0.9% saline at a dose of 15 mg/kg per body weight, once a week for two weeks. 
Animals were given free access to standard lab chow and water during the injection 
period. One week following the second injection, the animals were randomly divided into 
six groups, each containing eight animals. Each anim l group received a different 
experimental diet for eight weeks that was modified with respect to pyridoxine and casein 
content (Table 1). Food consumption was measured twice a week. The complete 
composition of the experimental diets is shown in Appendix B, Table 1.  
 
Body weights of the animals were monitored weekly during dietary treatment and at 
termination. Animals were terminated after eight weeks of feeding (nine weeks after the 
last AOM injection). Prior to termination, animals were fasted for 24 hours and sacrificed 
by CO2 asphyxiation. After recording body weight, blood was collected. Whole blood 
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was sent for CBC analysis using rat specific parameters. Plasma samples were analyzed 
for biochemistry and assessed for levels of homocysteine, cysteine and PLP and oxidative 
stress markers 3-OH-DG and 3-nitrotyrosine. Weights of heart, liver, spleen and kidney 
were recorded and samples were stored at -80ºC for futu e analysis. Any pathologic 
anomalies observed with the naked eye were recorded as general observations. Colons 
were fixed and analyzed for growth and development of ACF. Liver tissue was analyzed 
for levels of oxidative stress markers. 
 
 
Table 1. Composition of experimental diet groups 
Experimental Diet Groups Protein (Casein) Vitamin B6 
High Protein, Low B6 400 g/Kg 3.5 mg/kg 
High Protein, Normal B6 400 g/Kg 7 mg/kg 
High Protein, High B6 400 g/Kg 14 mg/kg 
Normal Protein, Low B6 200 g/Kg 3.5 mg/kg 
Normal Protein, Normal B6 200 g/Kg 7 mg/kg 





Figure 6. Schematic representation of the experimental protocol for male Sprague-
Dawley rats receiving diets varying in protein and vitamin B6 
Red arrows designate AOM injections. Animals were fd standard lab chow during 
carcinogen injection. One week after the second injection, the animals were randomly 
divided into six groups and placed on experimental diets. Animals were terminated after 
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3.3 Results  
3.3.1 Diet Consumption and Weekly Body Weights  
The amount of diet consumed by each treatment group and the body weights of each rat 
were monitored weekly. A graph describing the trend of ietary consumption is shown in 
Figure 6 (for details see Appendix C, Table 2). In week 1, the amount of food consumed 
was similar between the treatment groups. The amount f food consumed in week 2 
decreased approximately 40% across all treatment groups. As dietary treatment continued 
from week 3 to week 8, the high protein, low B6 group consumed 100-250 grams more 
than all other groups. It was noted that the amount f food consumed and body weights of 
the high protein, low and normal B6 and normal protein, low B6 groups were always 
similar to each other and lower than the remaining three treatment groups. The trend in 
weekly diet consumption is reflected in the weekly average weight of a rat in each 
treatment group. The average weekly weight of an anim l in each treatment group is 
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Figure 7. Mass of diet consumed weekly by male AOM-injected Sprague-Dawley 
rats after eight weeks of intervention with diets varying in protein and vitamin B6 
High Protein  Normal  Protein  
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3.3.2 Final Organ and Body Weights 
At termination, the body and organ weights were reco ded. Groups of animals receiving 
high protein diets with normal and high B6 had significantly lower body weights than 
groups receiving normal protein with normal or high B6 (Table 3). In addition, it was 
noted that the animal group receiving high protein, low vitamin B6 had a significantly 
higher body weight than the other two high protein dietary groups. Statistically, a dual 
effect of protein and vitamin B6 was observed on the animal groups through body weight. 
 
With the exception of the heart, the organ weights of the high protein, low B6 animal 
group were higher than the other groups (Table 3). In particular, the average kidney 
weight of this group was significantly higher than that of the others. As a group, animals 
receiving high dietary protein had significantly hig er kidney weights than the kidney 
weights of the groups receiving normal protein. And while not significantly higher, the 
average liver weight of the high protein, low B6 animal also appeared noticeably higher 
than that of the other groups.  
 
Table 2. Main effect of dietary protein and vitamin B6 on final body and organ 
weights in AOM-injected male Sprague-Dawley rats after eight weeks of treatmenta. 
Variable Protein Effect Vitamin B6 Effect 
B6*Protein 
Interaction 
Body Weight P = 0.085 P = 0.760 P = 0.031 
Heart P = 0.822 P = 0.845 P = 0.141 
Liver P = 0.908 P = 0.278 P = 0.021 
Kidney P = 0.007 P = 0.165 P = 0.194 
Spleen P = 0.852 P = 0.318 P = 0.098 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA 







Table 3. Final body and organ weights of AOM-injected male Sprague-Dawley rats after eight weeks of diet intervention 
including changes to dietary protein and vitamin B6
a 
Group Body Weight (g) Heart Weight (g) Liver Weight (g) Kidney Weight (g) Spleen Weight (g) 
High Protein, Low B6 550.0±14.9
x 4.2 ± 0.1x 17.5 ± 0.9x 4.1 ± 0.1x 1.0 ± 0.1x 
High Protein, Normal B6 498.6±11.6
y 3.8 ± 0.2x 13.9 ± 0.5y 3.7 ± 0.1w 0.9 ± 0.05xy 
High Protein, High B6 501.6±18.5
y 3.8 ± 0.2x 15.4 ± 0.7xy 4.0 ± 0.1xy 0.85±0.03y 
Normal Protein, Low B6 521.2±20.1
xy 3.8 ± 0.1x 14.9 ± 0.9y 3.6 ± 0.1wy 0.9 ± 0.06xy 
Normal Protein, Normal B6 549.0±19.1
x 4.0 ± 0.1x 15.9 ± 0.9xy 3.6 ± 0.2wy 0.90 ± 0.05xy 
Normal Protein, High B6 551.5±13.4
x 4.0 ± 0.2x 15.8 ±0.9xy 3.7 ± 0.2wy 1.00 ± 0.05xy 
 
aValues are mean ± SE of eight animals. Means within a column not sharing a common superscript (x, y, z) are significantly 





3.3.3 Hematological Status  
Following termination, whole blood of Sprague-Dawley rats was analyzed for complete 
blood count (Appendix C, Table 3). Dietary protein xerted effects on a selected number of 
hematological parameters. Platelet count as well as monocyte count, were significantly lower 
in rats receiving a high protein diet (P≤0.05). Analysis of lymphocytes indicated that vitamin 
B6 was having an effect. Lymphocyte counts in groups receiving high vitamin B6 treatment 
were lower than in the groups receiving low (P=0.107) and normal B6 (P=0.018).  
 
3.3.4 Clinical Status  
The effect varying dosages of protein and vitamin B6 has on plasma biochemistry was 
measured and compared (Appendix C, Table 4). One specific trend observed was the effect 
of increased dietary protein on a number of biochemical parameters. As a group, high protein 
significantly increased plasma urea and AST compared to normal protein (Table 6). The 
high-protein group also had significantly lower HDL-C and cholesterol compared to those 
that received a normal level of protein (P≤0.05). Yet, a comparison by individual treatment 
groups indicates that the level of HDL-C and cholesterol in plasma of the high protein, low 
B6 group was comparable to that in the normal protein, low B6 group. Also, the high protein 
group had significantly lower triglycerides when compared to the normal protein group. 





Table 4. Complete blood count analyses for AOM-injected male Sprague-Dawley rats 
after eight weeks of intervention with diets varying in protein and vitamin B6
a 
 High Protein Normal Protein 
Parameters Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
Platelet 
(10^9/L) 








0.29±0.04xy 0.21±0.02xy 0.24±0.06x 0.31±0.05 x 0.28±0.05xy 0.40±0.05y 
 
aValues are mean ± SE of eight animals. Means within a row not sharing a common 




Table 5. Main effect of dietary protein and vitamin B6 on hematological markers in 
AOM-injected male Sprague-Dawley rats after eight weeks of treatmenta. 
Hematological 
Marker Protein Effect Vitamin B6 Effect 
Protein* B6 
Interaction 
Platelet P = 0.024 P = 0.711 P = 0.763 
Lymphocyte Count P = 0.438 P = 0.052 P = 0.295 
Monocyte Count P = 0.020 P = 0.275 P = 0.292 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 










Table 6. Clinical status of AOM-injected male Sprague-Dawley rats after eight weeks of 
intervention with diets varying in protein and vitamin B6
a 
aValues are mean ± SE of eight animals. Means within a row not sharing a common 
superscript (x, y, z) are significantly different (P≤0.05, two-way ANOVA analyses with LSD 




Table 7. Main effect of dietary protein and vitamin B6 on clinical status in AOM-
injected male Sprague-Dawley rats after eight weeks of treatmenta. 
Biochemistry 
Marker 
Protein Effect Vitamin B6 Effect 
B6*Protein 
Interaction 
Urea P = 0.020 P = 0.740 P = 0.120 
AST P = 0.000 P = 0.666 P = 0.141 
HDL-C P = 0.005 P = 0.952 P = 0.308 
Cholesterol P = 0.010 P = 0.828 P = 0.205 
Triglycerides P = 0.019 P = 0.181 P = 0.195 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 
post hoc tests. 
 
 
 High Protein Normal Protein 
 Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
Urea 
(mmol/L) 5.9±0.2
x 5.6±0.2x 5.1±0.3xy 4.6±0.3y 5.1±0.4xy 5.1±0.3xy 
AST (U/L) 103.3±8.2xz 99.6±5.1xz 109.0±4.2x 79.4±5.3y 92.8±5.7z 80.8±4.0y 
HDL-C 
(mmol/L) 1.8±0.1
xy 1.5±0.1x 1.6±0.2x 1.9±0.2xy 2.0±0.2y 2.0±0.2y 
Cholesterol 
(mmol/L) 
2.2±0.2 xy 1.8±0.1 x 1.9±0.2 x 2.2±0.2 xy 2.4±0.2 y 2.4±0.2 y 
Triglycerides 
(mmol/L) 
1.4±0.4x 0.8±0.1y 0.8±0.1y 1.4±0.3x 1.2±0.1x 1.7±0.2x 
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3.3.5  Levels of Hepatic Cholesterol 
To compare the concentration of cholesterol in hepatic tissue of the Sprague-Dawley 
treatment groups, an equal amount of protein, 50 µg, was loaded for each sample. Six 
samples of liver tissue from each treatment group were randomly selected for the cholesterol 
assay. The results of the liver cholesterol assay are illustrated in Figure 7. Analysis of plasma 
cholesterol indicated a significant decrease in levels by high protein dietary treatment. While 
not significant, a similar trend was observed in the analysis of liver cholesterol; Sprague-
Dawley rats receiving high dietary protein had lower h patic cholesterol (P=0.086). 
Furthermore, regardless of the protein level, treatm nt groups receiving high vitamin B6 had 
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Figure 8. Liver cholesterol levels in AOM-injected male Sprague-Dawley rats after 
eight weeks of intervention with diets varying in protein and vitamin B6. 
Values are expressed as mean ± SE, N=6 per group. Bars not sharing a common superscript 
(x, y) are significantly different (P≤0.05, ANOVA analyses with LSD post hoc tests). 
 
Table 8. Main effect of dietary protein and vitamin B6 on hepatic cholesterol in AOM-
injected male Sprague-Dawley rats after eight weeks of treatmenta. 
 Protein Effect Vitamin B6 Effect 
B6*Protein 
Interaction 
Cholesterol P = 0.086 P = 0.069 P = 0.752 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 
post hoc tests. 
y 








3.3.6 Enumeration of Aberrant Crypt Foci (ACF) 
After eight weeks of feeding the animals with the experimental diets, the animal’s colons 
were examined for preneoplastic changes and compared to a group of AOM-injected rats 
receiving normal levels of dietary protein and vitamin B6. An interesting trend was observed 
- the high protein, low B6 animal group had significantly lower total and primal ACF 
(P≤0.05) (Table 10). However, the average number of total crypts, intermediate and 
advanced ACF for the normal protein, high B6 group behaved similarly to the other groups 
with the exception of the high protein, low B6 group. The total ACF count and primal, 
intermediate and advanced classification for the high protein groups with normal and high B6 
behaved similarly to the normal protein groups with low and normal B6. 
 
Table 9. Main effect of dietary protein and vitamin B6 on ACF growth in AOM-injected 
male Sprague-Dawley rats after eight weeks of treatmenta. 
 Protein Vitamin B6 
Protein*Vitamin B 6 
Interaction 
Total ACF P = 0.145 P = 0.132 P = 0.255 
Primal ACF P = 0.174 P = 0.135 P = 0.176 
Intermediate ACF P = 0.320 P = 0.756 P = 0.390 
Advanced ACF P = 0.718 P = 0.487 P = 0.421 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 








Table 10. Enumeration of ACF growth characteristics1,2 in AOM-injected male Sprague-Dawley rats after eight weeks of 
intervention with diets varying in protein and vitamin B6 
Diet Group Total ACF Primal ACF  
(1-3 Crypts) 
Advanced ACF  
(4-6 Crypts) 
Intermediate ACF  
(≥ 7 Crypts) 
High Protein, Low B6 210.1 ± 22.8
x 190.4±17.8x 19.0±5.3x 0.7±0.4x 
High Protein, Normal B6 301.6 ± 31.0
y 281.1±28.7y 19.8±3.3x 0.8±0.5x 
High Protein, High B6 320.0 ± 15.9
y 301.8±17.9y 17.1±2.9x 1.1±0.4x 
Normal Protein, Low B6 309.0 ± 33.7
y 289.1±31.8y 20.4±3.7x 0.4±0.2x 
Normal Protein, Normal B6 313.0 ± 24.7
y 289.9±23.5y 18.8±3.6x 1.1±0.6x 
Normal Protein, High B6 323.3 ± 46.9
y 294.8±23.5y 27.3±6.1x 1.3±0.6x 
  
1. Values are expressed as mean ± SE. N=7 for high protein, low B6 group, and N=8 all other groups. 
2. Values in the same column not sharing a common super cript are significantly different (P≤0.05, ANOVA analyses with LSD 





3.3.7 Plasma Markers of the Transulfuration Pathway  
Plasma levels of pyridoxal-5’-phosphate (PLP), the active form of vitamin B6, were 
measured by HPLC analysis as described previously. Five plasma samples from each group 
were randomly selected for analysis. Sprague-Dawley rats receiving normal protein, high 
vitamin B6 treatment had significantly higher levels of plasm PLP (P≤0.05) (Table 11). The 
level of plasma PLP in the high protein, low B6 group was comparable to the two other high 
protein groups and the normal protein groups containing low and normal vitamin B6.  
 
The levels of plasma homocysteine and cysteine did not change in a consistent manner; the 
results are summarized in Table 11. Five plasma samples from each group were analyzed. 
Compared to the groups receiving normal dietary protein, the high protein groups had 
reduced plasma homocysteine levels (p=0.101). The lev l of plasma cysteine in the normal 
protein, high B6 group was lower than the high protein groups receiving low and high B6 
(p≤0.05). The normal protein, low B6 group also had higher plasma cysteine than the normal 
protein, high B6 group (p≤0.05). With the exception of the high protein, normal B6 group, it 
was observed that vitamin B6 was lowering cysteine levels with increased dosage (P=0.092). 
 
The level of GSH in plasma was assayed by colorimetc determination as previously described. 
Dietary treatment of vitamin B6 was observed to exert an effect on the level of plasma 
glutathione (p=0.079). Sprague-Dawley rats receiving low vitamin B6 had lower levels of GSH 
than normal (P=0.030) and high B6 (P=0.074) treatment groups. The highest levels of reduced 
GSH in plasma were measured in the normal protein groups receiving normal and high B6. 
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Table 11. Plasma pyridoxal 5’-phosphate, homocysteine, cysteine and glutathione levels1,2,3 in 
AOM-injected male Sprague-Dawley rats after eight weeks of intervention with diets varying 
in protein and vitamin B6 
 High Protein Normal Protein 
 Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
PLP 
(nmoles/L) 
985.3±130.1x 1063.6±191.8x 955.9±115.8x 974.4±113.2x 988.5±80.3x 1577.4±210.0y 
Homocysteine 
(µM) 
5.9 ± 0.7xy 6.0 ± 0.3xy 5.3 ± 0.4x 6.5 ± 0.9xy 7.2 ± 0.8y 6.2 ± 0.8xy 
Cysteine 
(µM) 
249.5±6.6x 208.9±13.0y 257.2±8.1x 244.7±17.9xy  226.6±16.1xy 210.1±10.9y 
GSH (µM) 314.8±53.5xy 332.5±45.5xy 345.7±5.3xy 270.1±26.3y 401.6±15.0x 362.9±34.6x 
 
1. Values are expressed as mean ± SE. N=5 for all dietary treatment groups. N=5 for all 
assays.  
2. Values in the same row not sharing a common superscript (x, y, z) are significantly 
different (P≤0.05, ANOVA analyses with LSD post hoc tests). 
3. Abbreviations are as follows: PLP, Pyridoxal 5’-Phosphate; GSH, glutathione. 
 
 
Table 12. Main effect of dietary protein and vitamin B6 on plasma PLP, homocysteine, 
cysteine and GSH in AOM-injected male Sprague-Dawley rats after eight weeks of 
treatmenta. 
Variable Protein Effect Vitamin B6 Effect 
Protein* B6  
Interaction 
PLP P = 0.151 P = 0.135 P= 0.050 
Homocysteine P = 0.101 P = 0.447 P = 0.912 
Cysteine P = 0.286 P = 0.092 P = 0.053 
GSH P = 0.618 P = 0.079 P = 0.264 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 




3.3.8 Oxidative Stress Assessment 
Vitamin B6 altered GSH levels in hepatic tissue (P≤0.05) (Figure 8). With increasing levels 
of vitamin B6, the level of liver GSH increased. The high protein, normal B6 group had 
significantly higher GSH level than the normal protein, low B6 group (P≤0.05).  Significant 
differences were not observed in hepatic NO2
- (Figure 9) and in the activities of antioxidant 
enzymes SOD and CAT (Table 14). 
 
Sprague-Dawley plasma was also analyzed for 8-hydrox -deoxyguanosine (8-OH-DG) and 
3-nitrotyrosine. Since 8-OH-DG is a representative ROS biomarker and nitrotyrosine is a 
marker for RNS, we were able to gain further insight into the affect of dietary treatment on 
the redox balance within the plasma. Five plasma samples from each dietary treatment group 
were selected for both analyses. Dietary protein had a significant effect on the levels of 
plasma 8-OH-DG (P≤0.05) (Figure 10). Results from 8-OH-DG analysis in plasma 
demonstrate a stepwise increase in the levels of the biomarker moving from the high protein, 
low B6 group to the normal protein, high B6 group. The level of dietary protein also had a 
significant affect on hepatic nitrotyrosine concentrations (P≤0.05) (Figure 11). Animals 
receiving high protein had lower levels of liver nitrotyrosine than normal protein groups. The 
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Figure 9. Hepatic glutathione levels in AOM-injected male Sprague-Dawley rats after 
eight weeks of intervention in dietary protein and vitamin B6 
Values are expressed as mean ± SE, N=6 per dietary group. Bars not sharing a common 
superscript (x, y, z) are significantly different (P≤0.05, ANOVA analyses with LSD post hoc 
tests). Abbreviation: GSH, glutathione. 
 
 
Table 13. Main effect of dietary protein and vitamin B6 on hepatic GSH and NO2
- in 
AOM-injected male Sprague-Dawley rats after eight weeks of treatmenta. 
  
Protein Effect Vitamin B6 Effect 
Protein*Vitamin B 6 
Interaction 
GSH P = 0.270 P = 0.030 P = 0.000 
NO2
- P = 0.607 P = 0.637 P = 0.257 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 
post hoc tests. 
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Figure 10. Hepatic nitrite levels in AOM-Injected male Sprague-Dawley rats after eight 
weeks of intervention with diets varying in protein and vitamin B6 
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Table 14. Superoxide dismutase and catalase activities1,2,3,4,5 in liver tissue of AOM-
injected male Sprague-Dawley rats after eight weeks of intervention with diets varying 
in protein and vitamin B6 
 High Protein Normal Protein 
 Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
SOD 
(U/mg) 
0.09 ± 0.02x  0.11±0.02xy 0.06 ± 0.01x 0.06 ± 0.02x 0.16 ± 0.03y 0.09 ± 0.01x 
CAT 
(U/mg) 
1434.8±199.8 1301.9±76.8 1257.3±196.0 1445.0±80.0 1337.4±102.3 1276.2±214.4 
 
1. Values are expressed as mean ± SE, N=6 for all treatment groups. 
2. Values in the same row not sharing a common superscript (x, y) are significantly 
different (P≤0.05, ANOVA analyses with LSD post hoc tests). 
3. For SOD activity, one unit is defined as the amount of enzyme needed to exhibit 50% 
dismutation of the superoxide radical. 
4. For CAT activity, one unit is defined as the amount of enzyme that will cause 
formation of 1.0 nmol formaldehyde per minute at 25°C. 




Table 15.  Main effect of dietary protein and vitamin B6 on hepatic SOD and CAT 
activities in AOM-injected male Sprague-Dawley rats after eight weeks of treatmenta. 
Antioxidant 
Enzyme 
Protein Effect Vitamin B6 Effect 
Protein*Vitamin B 6 
Interaction 
SOD P = 0.369 P = 0.006 P = 0.118 
CAT P = 0.867 P = 0.533 P = 0.997 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 
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Figure 11. Level of plasma 8-OH-DG in AOM-injected male Sprague-Dawley rats after 
eight weeks of intervention with diets varying in protein and vitamin B6 
Values are expressed as mean ± SE, N=5 for all dietary treatment groups. Bars not sharing a 
common superscript are significantly different (P≤0.05, ANOVA analysis with LSD post hoc 
tests). Abbreviations: 8-OH-DG, 8-hydroxy-2-deoxyguanosine; AOM, azoxymethane. 
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Figure 12. Level of plasma 3-nitrotyrosine in AOM-injected male Sprague-Dawley rats 
after eight weeks of intervention with diets varying in protein and vitamin B6 
Values are expressed as mean ± SE, N=5 for all dietary treatment groups. Bars not sharing a 
common superscript are significantly different (P≤0.05, ANOVA analysis with LSD post hoc 
tests).  
 
Table 16. Main effect of dietary protein and vitamin B6 on plasma 8-OH-DG and N-
tyrosine in AOM-injected male Sprague-Dawley rats after eight weeks of treatmenta. 
Oxidative Stress 
Marker 
Protein Effect Vitamin B6 Effect 
Protein*Vitamin B 6 
Interaction 
8-OH-DG P = 0.000 P = 0.149 P = 0.921 
N-Tyrosine P = 0.000 P = 0.906 P = 0.874 
aEffect is significant if P≤0.05. Statistical analysis is based on a two-way ANOVA with LSD 
post hoc tests. 









The study was designed to determine if a high protein diet will compromise the vitamin B6 
status which, in turn, will affect the measurements reflecting impaired amino acid 
metabolism, an increase in oxidative stress markers and growth of ACF. It was noted that the 
group fed high protein in combination with low B6 had the lowest number of ACF. It became 
apparent that the level of protein was an important variable in altering a number of 
physiological parameters. The plasma level of cholesterol, platelet and monocytes counts, 
and the oxidative stress markers were lower in high protein than in normal protein groups. 
The level of B6 was selected based on the normal recommended level in the rodent diet. It is 
possible that the recommended level, with a safety factor, is sufficient even if one increases 
the amount of protein in the diet, as was done in the present study. Since ACF number was 
lower in the high protein, low B6 group, it can be suggested that preneoplastic lesions also 
require adequate vitamin B6 for their growth. The normal protein diet contained higher 
carbohydrates than the high protein diet. Oxidative str ss markers were higher in the normal 
protein group than the high protein group. Again, these differences could have been due to 
high carbohydrates and rising glucose burden and metabolism, leading to a resulting increase 
RNS and ROS production.  
 
As expected, Sprague-Dawley rats receiving a supplementary amount of pyridoxine at 14 
mg/kg (normal protein, high B6 group) had the highest concentration of plasma PLP. 
Previous research reports an inverse correlation between the concentrations of circulating 
vitamin B6 compounds (urinary 4-pyridoxic acid and plasma pyridoxal 5’-phosphate) and 
protein intake (Miller et al. 1985). It has been suggested that as the level of dietary protein is 
increased, more vitamin B6 is removed from circulation and retained in the liver to supply 
PLP to PLP-dependent enzymes involved in the catabolism of excess amino acids. As a 
result, less vitamin B6 is available for conversion to 4-PA and PLP (Miller et al., 1985 and 
Lumeng et al., 1974). Unlike previous studies, results of plasma PLP analyses from high 
protein groups in this study did not follow this trend. Plasma PLP levels in the high protein 
group did not vary significantly from the normal protein, low and normal B6 groups. With the 
high protein, high B6 group specifically, it is plausible that the amount of pyridoxine 
treatment was sufficient to balance out the requirements of PLP-dependent enzymes and 
 
55 
maintain redox balance despite increases in protein. Yet, the plasma PLP levels in the high 
protein, low and normal B6 groups were contrary to our hypothesis.  There is some evidence 
to suggest that, in rats, plasma PLP levels may not accurately reflect vitamin B6 status 
(Schaeffer et. al., 1989). We also know that protein metabolism was increased in the livers of 
high protein, normal and low B6 groups as evidenced by plasma urea concentrations. The 
metabolism of proteins and amino acids in these groups resulted in an increase in 
deamination leading to urea as the final degradation pr duct for excretion of excess nitrogen. 
This corresponds to previous research that indicates n increase in urea synthesis during high 
dietary protein intake and would suggest a greater requirement for PLP as coenzyme for 
protein metabolism in the liver of these groups (Saheki et. al., 1978). Therefore, before 
concluding that a low and normal B6 dose is adequate during high protein intake, additional 
experiments evaluating vitamin B6 status would be recommended. Experiments could incude 
measuring urinary 4-PA excretion, erythrocyte alanine or aspartate aminotransferase 
stimulation and microbiological assessment in hepatic tissue using Saccharomyces uvarum. 
 
No definite trend was observed for plasma PLP, homocysteine and cysteine in the treatment 
groups. The metabolism of homocysteine to cysteine requires PLP as cofactor for two 
enzymes in the transulfuration pathway. By supplementing pyridoxine, a decrease in plasma 
homocysteine and an increase in cysteine were expected. From the results, one can conclude 
that vitamin B6 at different levels of protein did not affect this pathway. 
 
GSH is an important antioxidant and the cellular concentration of this metabolite has a major 
effect on antioxidant function. There was no consistent affect of dietary treatment on plasma 
and liver GSH.  
 
Vitamin B6 had no effect on plasma 3-nitrotyrosine. Rather, protein intake affected levels of 
3-nitrotyrosine. High protein had lower levels of 3-nitrotyrosine compared to normal protein.  
3-Nitrotyrosine is marker used to detect the presence of peroxynitrite (ONOO-) and is 
produced from a reaction between ONOO- and L-tyrosine (Maruyama et. al., 1996). The 
formation of ROS and RNS during oxidative stress can be assessed by their reaction 
products. Nitric oxide (NO) and superoxide anion may react together to produce ONOO-.  
Peroxynitrite is a more active molecule and a powerful oxidizing agent that can initiate 
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nitration and hydroxylation of aromatic rings (Kumarathasan and Vincent, 2003). 
Peroxynitrite can cause DNA fragmentation and lipid oxidation. Since 3-nitrotyrosine is a 
biomarker ONOO- and groups receiving high protein had lower levels of the nitrated 
aromatic ring, one can suggest that high protein or low carbohydrate diet lead to less 
oxidative damage than normal protein counterparts.  
 
In addition to forming peroxynitrite, NO is also oxidized to nitrite and nitrate. Since NO2
- 
also serves as a marker of NO, a trend similar to 3-nitrotyrosine levels was expected. The 
level of liver NO2
- did not vary significantly among treatment groups. This could be 
attributed to the sensitivity of the techniques used. The high performance liquid 
chromatography method used to detect nitro-tyrosine has been documented to be a more 
sensitive assay than the one used to calorimetrically determine nitrite concentration. Another 
factor that might have affected colorimetric determination of nitrite was interferences due to 
antioxidants and nucleophiles (i.e. GSH and cysteine). 
 
The most pro-mutagenic oxidation product of guanine is 8-hydroxy-2-deoxyguanosine (8-
OH-DG) (Thompson, 2006). It is easily formed and is a potential biomarker for 
carcinogenesis as it can give rise to G-to-T transversion mutations in several genes 
(Thompson, 2006). A stepwise trend was observed for plasma 8-OH-DG results. By 
increasing dietary protein and decreasing B6 intake, the production of 8-OH-DG was 
decreased. In early carcinogenesis, the high protein di t in combination with low B6 had the 
lowest concentration of plasma 8-OH-DG and ACF count. O e can infer from this result that 
sensitivity to ACF development could be decreased by increasing protein or lowering 
carbohydrate, while maintaining adequate B6 intake. 
 
In conclusion, different levels of vitamin B6 did not affect early stages of carcinogenesis and 
did not have a significant effect on the antioxidant status. Contrary to the hypothesis, low 
vitamin B6 in combination with high protein reduced the growth and development of ACF. 
This study also demonstrated that protein and/or carbohydrate level is an important 






Study 2: The Role of Supplemental Vitamin B 6 as a Biochemical 
Response Modifier of Colon Carcinogenesis in Obesit y 
4.1 Study Background and Specific Aims 
The ability of vitamin B6 to exert a noticeably protective effect and lower oxidative stress 
could be dependent on the concentration of pyridoxine supplemented and the health of the 
subject. Humans and experimental animal models diagnosed as Type 1 and Type 2 diabetics 
have been shown to exhibit vitamin B6 deficiency (Davis et. al., 1976 and Nair et. al., 1998). 
Hyperglycemia, a hallmark of diabetes, is known to generate reactive oxygen species 
(Brownlee, 2001). In vitro, vitamin B6 supplementation has been shown to inhibit superoxide 
radicals, lipid peroxidation and protein glycosylation in human erythrocytes treated with high 
glucose (Jain and Lim, 2000). Supplementation with v amin B6 has also been shown to 
lower blood glucose in streptozotocin-treated diabetic animals and glycosylated hemoglobin 
levels in Type 2 diabetic patients (Nair et. al., 1998). To date there is no experimental 
evidence documenting the effect of B6 supplementation on oxidative stress in diabetic 
patients and animals (Jain, 2007).  
 
Zucker Obese rats are hyperglycemic and at risk of developing Type 2 diabetes. High 
concentrations of circulating glucose are a symptom f hyperphagia caused by the 
inheritance of non-functional leptin receptors of the Zucker animal model (Bray, 1977). As 
previously mentioned, hyperglycemia generates oxidative stress. Additionally, the Zucker 
Obese animal model is known for representing a sustained inflammatory state and having an 
increased sensitivity to colon cancer (Gunter and Leitzmann, 2006). It is postulated that the 
heightened sensitivity of these animals to colon carcinogenesis is due to obesity associated 
pro-inflammatory responses and elevated levels of reactive oxygen species.  
 
In this study, it was hypothesized that if B6 functions as an antioxidant, then supplemental B6 
will alleviate ROS and will reduce sensitivity of the colon to the number and growth of ACF, 
preneoplastic lesions. In the first study, low or high B6 (2x higher than recommended intake) 
did not change the oxidative status of Sprague-Dawley rats. Therefore, it was reasoned that, 
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possibly, a supraphysiological dose of pyridoxine would serve as an antioxidant. Hence, it 
was prudent to use an animal model with a pre-existing physiological state identified to be 
pro-inflammatory and high in oxidative stress. 
 
The specific aims of this study were:  
 To assess if supplemental vitamin B6 lowers progression of colon cancer in Zucker 
Obese rats in post-initiation stages.  
 To measure tissue levels of oxidative stress markers. 
 
4.2 Methodological Approach  
A group of AOM-injected Zucker Obese rats receiving a diet high in vitamin B6 was 
compared to a treatment group consuming the recommended level of vitamin intake. A 
detailed summary of the study design is illustrated in Figure 12. Six week old female Zucker 
Obese (n=16) and Zucker Lean rats (n= 20) arrived from Charles River Canada and were 
housed in the Animal Facility. During the first week, rats were acclimated to laboratory 
conditions and given free access to standard lab chow. Following acclimation, animals were 
placed on experimental diets varying in the level of vitamin B6 for two weeks (Table 17). 
One Zucker Obese animal group received high vitamin B6 (35 mg/kg PN-HCl) while another 
received the recommended amount (7 mg/kg PN-HCl). Both Zucker lean groups received 7 
mg/kg PN-HCl. After two weeks of feeding, animals were subcutaneously injected with 
AOM, diluted in 0.9% saline at a dose of 10 mg/kg body weight. Animals received a second 
injection two weeks later. Animals were given free access to the experimental diets during 
and following the injection period. Body weights were monitored weekly during the entire 
study and six weeks after the last AOM injection, animals were fasted for 24 hours and 
terminated by CO2 asphyxiation. After recording body weight, blood was obtained and sent 
for CBC, biochemical, homocysteine, cysteine and PLP analysis. Weights of heart, liver, 
spleen and kidney were recorded and samples were stor d at -80ºC for future analysis. Any 
pathologic anomalies noted by the naked eye were record d as general observations. Colons 
were analyzed for the growth and development of ACF and liver tissue was analyzed for 






















Blue arrows represent AOM injections and black arrows represent animal termination. 
Animals were randomly housed in groups of three or fou and began feeding on experimental 
diets two weeks prior to carcinogen injection. Animals were terminated six weeks after the 
second injection. 
 
Table 17. Amount of vitamin B6 in experimental diets of Zucker Obese and Lean study 
Group Vitamin B 6 (mg/kg) 
Group OH:  Zucker Obese, High B6 35 
Group ON:  Zucker Obese, Normal B6 7 
Group LN:  Zucker Lean, Normal B6 7 
Group LC:  Zucker Lean Control, Normal B6 7 
 
Figure 13. Schematic representation of the experimental protocol for effect of 




4.3.1 Body and Organ Weights  
At termination, the body and organ weights of the rats were recorded (Table 18). A 
significant difference between the body weights of Zucker Obese rats receiving normal and 
high B6 was not observed. Differences in heart and kidney wights were also not observed 
between the two obese feeding groups. However, significa t differences were observed in the 
liver and spleen weights of Zucker Obese rats receiving normal B6 (Zk-OBN) and high B6 
(Zk-OBH) (p≤0.05). Zucker Obese rats receiving five times the regular does of vitamin B6 
had significantly lower liver weights than those receiving normal levels. During necropsy, 
the gross appearances of the organs were assessed blindly. The coloration of livers in the Zk-
OBH group appeared darker pink and less marble-like in pattern compared to their normal B6 
counterparts. The body and organ weights of Zucker Lean animals were significantly lower 
than both obese treatment groups (p≤0.05).   
 
Table 18. Final body and organ weights1,2,3 of AOM-injected female Zucker Obese and 
Lean rats after dietary treatment with vitamin B6 
Group Body Weight (g) Liver (g) Kidney (g) Heart (g) Spleen (g) 
Zk-OBN 550.8 ± 13.5x 43.8 ± 2.5x 4.0 ± 0.2x 1.3 ± 0.0x 1.1 ± 0.0x 
Zk-OBH 557.2 ± 9.8x 37.4 ± 2.7y  3.8 ± 0.2x 1.3 ± 0.0x 0.9 ± 0.0y 
Zk-LN 267.0 ± 8.4y 9.0 ± 2.7z 2.2 ± 0.1y 1.0 ± 0.0y 0.5 ± 0.0z 
  
1. Values are expressed as mean ± SE, N=8.  
2. Values in the same column without a common superscript are significantly different 
(ANOVA analysis with LSD post hoc tests). 
3. Abbreviations are as follows: Zk-OBN, Zucker Obese rats receiving normal levels of 
Vitamin B6; Zk-OBH, Zucker Obese rats receiving high Vitamin B6; Zk-LN, AOM-




4.3.2 Hematological Status  
 
Whole blood from Zucker Obese and Lean rats was analyzed for complete blood count 
(Appendix C, Table 6). Platelet counts from Zucker Obese rats receiving high B6 and the 
Zucker Lean group were significantly lower than theZucker Obese group receiving normal B6 
(P≤0.05) (Table 19). Zucker Obese rats receiving high B6 had significantly lower monocyte 
counts compared to the Zucker Obese normal B6 group (P≤0.05). While not significant, the 
lymphocyte count of Zucker Obese rats receiving high B6 was lower than the normal B6 group 
(p=0.098) and Zucker Lean rats (p=0.366). 
 
 
Table 19. Hematological status1,2,3 of AOM-injected female Zucker Obese and Lean rats 
after receiving vitamin B6 treatment 
Parameters Zk-OBN Zk-OBH Zk-LN 
Platelets (10^9/L) 975.4 ± 43.3x 833.5 ± 46.8y 800.3 ± 59.4y 
Lymphocyte (10^9/L) 4.7 ± 0.7x 3.0 ± 0.6x 3.9 ± 0.9x 
Monocyte (10^9/L) 0.4 ± 0.1x 0.3 ± 0.0 y 0.1 ± 0.0 y 
 
1. Values are expressed as mean ± SE. N=8 for Zk-OBN and Zk-OBH dietary groups 
and N=6 for Zk-LN.  
2. Values in the same row without a common superscript a e significantly different 
(P<0.05, ANOVA analyses with LSD post hoc tests).  
3. Abbreviations: Zk-OBN, Zucker Obese normal B6 group; Zk-OBH, Zucker Obese 
high B6 group; Zk-LN, AOM-injected Zucker Lean rats receiving normal B6. 
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4.3.3 Clinical Assessment  
 
The effect of vitamin B6 on plasma biochemistry in Zucker Obese and Lean rats w s 
analyzed and compared (Appendix C, Table 7). Total protein was higher in the Zucker Obese 
group receiving normal B6 than the high B6 treatment group (p=0.095) and significantly 
greater than the Zucker Lean group (P≤0.05) (Table 20). A significant difference in glucose 
was not observed between the Zucker Obese normal B6 and high B6 groups. However, 
glucose in Zucker Lean rats was significantly lower than the obese groups. Initial analysis of 
triglyceride values in the Zucker Obese group with N=8 indicated that Zk-OBH had higher 
levels compared to Zk-OBN and Zk-LN. However, after removal of an outlier that was 
greater than 3 standard deviations in the Zk-OBH group, a significant difference in the level 
of plasma triglycerides did not exist between the two obese treatment groups (Figure 13).  
 
Table 20. Clinical assessment1,2,3 of AOM-injected female Zucker Obese and Lean rats 
after receiving B6 treatment 
Biochemical 
Parameters Zk-OBN Zk-OBH Zk-LN 
Total Protein (g/L) 80.0 ± 1.7x 76.4 ± 1.4x 75.0±1.3y 
Cholesterol (mmol/L) 11.9 ± 0.4x 9.5 ± 1.1y 2.5 ± 0.2z 
Glucose (mmol/L) 14.8 ± 0.8x 14.9 ± 1.8x 7.6 ± 0.5y 
Triglycerides 
(mmol/L) 
3.5 ± 0.5xy 5.1 ± 1.4y 1.2 ± 0.3x 
ALT (U/L) 126.1 ± 35.1x 127.8 ± 19.9x 36.8 ±1.4y 
Globulin (g/L) 37.6 ± 0.8x 33.6 ± 1.4y 22.8 ± 1.3z 
1. Values are expressed as mean ± SE. N=8 for Zk-OBN and Zk-OBH dietary groups 
and N=6 for Zk-LN. 
2. Values in the same row without a common superscript a e significantly different 
(P<0.05, ANOVA analysis with LSD post hoc tests).  
3. Abbreviations: Zk-OBN, Zucker Obese normal B6 group; Zk-OBH, Zucker Obese 




































Figure 14. Plasma triglyceride levels after outlier removal in Zucker Obese and Lean 
rats after receiving B6 treatment 
Values are expressed as mean ± SE. An outlier was removed from Zk-OBH, therefore N=7. 
N=8 Zk-OBN and N=6 for Zk-LN. Bars without a common superscript are significantly 
different (P<0.05, ANOVA analysis with LSD post hoc tests). Abbreviations: Zk-OBN, 
Zucker Obese normal B6 group; Zk-OBH, Zucker Obese high B6 group; Zk-LN – AOM-





4.3.4 Liver Cholesterol Levels  
 
To compare the concentration of cholesterol in hepatic tissue of Zucker Obese and Lean rats, 
an equal amount of protein totaling 50 µg was loaded for all samples. Seven samples of liver 
tissue from each Obese treatment group were selected for assay while six samples were 
selected for the Zucker Lean group. Significant differences in liver cholesterol concentration 
were not observed between Zucker Obese rats receiving normal and high levels of pyridoxine 
(Figure 14). Moreover, significant differences in liver cholesterol were not observed between 






























Figure 15. Liver cholesterol levels in Zucker Obese and Lean rats after receiving B6 
treatment. 
Liver cholesterol levels were assayed using the Amplex Red kit by fluorometric detection. 
For each sample, a volume equal to 50 µg of protein was used to detect cholesterol level. All 
values are mean ± SE. N=7 for Zucker Obese dietary treatment groups and N=6 for the 
Zucker Lean group. Abbreviations:  Zk-OBN, Zucker Obese rats receiving normal levels of 
vitamin B6; Zk-OBH, Zucker Obese rats receiving high vitamin B6; Zk-LN, AOM-injected 





4.3.5 Enumeration of Aberrant Crypt Foci (ACF) 
 
Six weeks following the second AOM injection and after ten weeks of dietary treatment, the 
colons of Zucker Obese and Lean rats were fixed and examined for preneoplastic changes. 
The results of the quantification of ACF are summarized in Table 21. Zucker Obese rats 
receiving the normal B6 diet had a significantly higher amount of total ACF compared to the 
high B6 treatment group and Zucker lean animals (P≤0.05). Furthermore, the Obese group 
receiving normal B6 had significantly higher enumeration of primal (1-3 crypts) and 
intermediate ACF (4-6 crypts) compared to the Zucker Obese high B6 and Zucker Lean 
treatment groups (P≤0.05). The number of total crypts, primal and interm diate ACF were 
similar between the high B6 Zucker Obese group and Zucker Lean rats.  Differences were not 
observed in the enumeration of advanced ACF (7+ crypts) between any of the animal groups.  
 
 
Table 21. Enumeration of ACF growth characteristics in AOM-injected female Zucker 
Obese and Lean rats after receiving vitamin B6 treatment
a 




Advanced ACF       
(7+ Crypts) 
Zk-OBN 209.6 ± 19.5x 194.9 ± 17.7x 14.4 ± 2.5x 0.4 ± 0.3x 
Zk-OBH 151.3 ± 18.9y 141.6 ± 17.7y 9.4 ± 1.4y 0.3 ± 0.2x 
Zk-LN 135.0 ± 16.9y 128.6 ± 16.4y 6.3 ± 1.4y 0.2 ± 0.2x 
 
aValues are expressed as mean ± SE. N=8 per Zucker Ob se group and N=7 for Zk-LN. 
Values in the same column without a common superscript a e significantly different (P<0.05, 
ANOVA analysis with LSD post hoc tests). Abbreviations: ACF, aberrant crypt foci; Zk-
OBN, Zucker Obese normal B6 group; Zk-OBH, Zucker Obese high B6 group; Zk-LN, 







4.3.6 Plasma PLP, Homocysteine and Cysteine Measure ment  
 
Plasma of Zucker Obese rats was analyzed for PLP levels using a 3H-tyrosine radioenzymatic 
assay kit. Challenges were faced bleeding the animals during termination and a limited 
amount of blood was retained from each animal. As a result, plasma from Zucker Lean rats 
was unavailable for PLP analysis. Significant differences were not observed in PLP levels 
between Zucker Obese normal and high B6 treatment groups (Figure 15).  
 
Plasma samples of the Zucker Obese treatment groups and the Zucker Lean group were 
analyzed for homocysteine and cysteine by reverse phase HPLC as previously described 
(Table 22). After sending an adequate amount of plasma to Guelph Animal Laboratories for 
CBC and biochemical analysis, only four samples remained per Zucker Obese treatment 
group and three for the Zucker Lean group. A comparison of homocysteine concentration in 
Zucker Obese rats receiving normal B6 and high B6 did not indicate significant differences. 
However, the Zucker Lean animal group had a significantly higher concentration of 
homocysteine compared to both Zucker Obese groups (P≤0.05). Significant differences in the 
concentration of plasma cysteine were not observed b tween any of the Zucker Obese 






























Figure 16. Plasma PLP in AOM-injected female Zucker Obese rats after receiving 
vitamin B6 treatment 
Plasma PLP was measured using a commercially available r dioenzymatic assay kit. All 
values are mean ± SE, N=4 per dietary group. Abbreviations: PLP, pyridoxal 5’-phosphate; 
Zk-OBN, Zucker Obese rats receiving normal vitamin B6; Zk-OBH, Zucker Obese rats 




Table 22. Plasma cysteine and homocysteine concentrations in female AOM-injected 
Zucker Obese and Lean rats after vitamin B6 treatment
a 
Parameter Zk-OBN Zk-OBH Zk-LN 
Homocysteine (µM) 2.87 ± 0.06x 3.09 ± 0.51x 6.21 ± 0.83y 
Cysteine (µM) 184.9 ± 6.0x 167.2 ± 13.3x 193.9 ± 13.3x 
 
aPlasma homocysteine and cysteine levels in Zucker Ob se and Lean were assayed by 
reverse phase HPLC analysis.  All values are mean ± SE. As a result of challenges 
experienced in bleeding the animals, a limited amount f plasma was available for analysis. 
Therefore, for cysteine and homocysteine analyses N=4 per Zucker Obese dietary group and 
N=3 for the Zucker Lean group. Values within a row without a common superscript (x, y) 
differ significantly (P<0.05, ANOVA analysis with LSD post hoc tests). Abbreviations: Zk-
OBN, Zucker Obese rats receiving normal levels of vitamin B6; Zk-OBH, Zucker Obese rats 
receiving high Vitamin B6; Zk-LN, AOM injected Zucker Lean group receiving normal 
vitamin B6.  
 
70 
4.3.7 Antioxidant Status  
The antioxidant status of Zucker Obese and Lean rats t eated with normal and high levels of 
vitamin B6 was assessed through a measurement of hepatic levels of GSH, NO2
-, antioxidant 
enzymes SOD, GPx and CAT. To determine the activities of antioxidant enzymes, hepatic 
tissue samples were homogenized in their respective buff rs and equal sample volumes were 
analyzed. 
 
To measure the level of GSH in hepatic tissue, an equal volume of whole liver extract was 
assayed for each sample. The results of the GSH assay re demonstrated in Figure 16. Seven 
liver samples for each treatment group were used for the assay. Zucker Obese rats receiving a 
diet high in vitamin B6 had significantly higher levels of GSH compared to counterparts 
receiving normal B6 (P<0.05). Interestingly, the level of GSH in Zucker Lean animals was 
similar to the Zucker group treated with high B6.  
 
NO2
- levels were measured as a marker for nitric oxide. Plasma of Zucker Obese rats was 
analyzed for nitrite levels (Figure 17A). Due to difficulties experienced in bleeding the 
animals at termination, only four plasma samples from the normal B6 group (Zk-OBN) and 
give samples from the high B6 group (Zk-OBH) were available for analysis. As a result of 
sending plasma samples for CBC, biochemical, homocysteine and cysteine analysis, plasma 
samples representative of the Zucker Lean group were unavailable for NO2
- analysis. While 
not significant, Zucker Obese rats receiving normal B6 had higher levels of plasma nitrite 
compared to the high B6 group. Whole extracts of hepatic tissue from both Zucker Obese 
treatment groups and the Zucker Lean group were assayed for nitrite level (Figure 17B). Six 
samples were selected from each treatment group. A similar trend observed for plasma NO2
- 
results between the normal and high B6 groups was observed in hepatic tissue; the ZK-OBN 
group had a significantly higher level of hepatic ntrite (P≤0.05). Furthermore, Zucker Lean 
rats had significantly higher levels of hepatic NO2
- than both Zucker Obese treatment groups 
(P≤0.05).  
 
For the SOD assay, six samples of hepatic tissue wer used from each Zucker Obese 
treatment group. All eight livers from the Zucker Lean group were used. Significant 
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differences were not observed in the activities of SOD between Zucker Obese and Lean 
treatment groups (Figure 18). For GPx and CAT activity assays, all eight livers were used 
from both Zucker Obese treatment groups. Livers of AOM-injected Zucker Lean rats were 
unavailable for GPx and CAT assay. Instead livers from non-injected Zucker Lean rats (lean 
control group) were used for comparison to activity in Zk-OBN and Zk-OBH rats. The 
results of the activities of GPx and CAT are summarized in Table 23.  The activity of GPx in 
Zk-OBN was significantly higher than Zk-OBH and Zk-LC (P≤0.05). Significant differences 
in CAT activity were not observed between both Zucker Obese treatment groups and the 
























Figure 17. Colorimetric determination of glutathione (GSH) in whole extracts of liver 
from female AOM-injected Zucker Obese and Lean rats after receiving vitamin B6 
treatment. 
GSH in liver tissue was assayed for Zucker Obese normal and high vitamin B6 treatment 
groups and Zucker Lean rats.  All values are mean ± SE, N=7 per dietary group. Bars without 
a common letter (x, y, z) differ significantly, P<0.05, ANOVA analyses with LSD post hoc 
tests. Abbreviations: GSH, glutathione; Zk-OBN, Zucker Obese rats receiving normal levels 
of vitamin B6; Zk-OBH, Zucker Obese rats receiving high vitamin B6; Zk-LN, AOM-injected 







Figure 18. Colorimetric determination of nitrite in  plasma and whole extracts of liver 
from female AOM-injected Zucker Obese and Lean rats after receiving vitamin B6 
treatment 
All values are mean ± SE. (A) Represents results of plasma nitrite measured in Zucker Obese 
treatment groups, Zk-OBN and Zk-OBH. Due to challenges with bleeding the animals at 
termination, N=4 for Zk-OBN and N=5 for Zk-OBH for plasma NO2
- measurement. Plasma 
from Zucker Lean rats was not available for analysis. (B) Represents hepatic nitrite levels in 
Zucker Obese and Zucker Lean treatment groups. N=6 for liver NO2
- measurement. Bars 
without a common letter (x, y, z) differ significantly, p≤0.05 as determined by ANOVA 
analyses in conjunction with LSD post-hoc tests. Abbreviations are as follows: Zk-OBN, 
Zucker Obese rats receiving normal levels of vitamin B6; Zk-OBH, Zucker Obese rats 












































































Figure 19. SOD activity in hepatic tissue of female AOM-injected Zucker Obese and 
Lean rats after receiving vitamin B6 treatment. 
 
Values are expressed as mean ± SE. N=6 per Zucker Obese dietary treatment group and N=8 
for the Zucker Lean group. One unit is defined as the amount of enzyme needed to exhibit 
50% dismutation of the superoxide radical. Abbreviations: Zk-OBN, Zucker Obese normal 
B6 group; Zk-OBH, Zucker Obese high B6 group; Zk-LN, AOM-injected Zucker Lean group 




Table 23. GPx and CAT activities in hepatic tissue1,2,3,4,5 of female AOM-injected 
Zucker Obese rats and non-injected Zucker Lean rats after receiving vitamin B6 
treatment 
Antioxidant Enzyme Zk-OBN Zk-OBH Zk-LC 
GPx Activity (U/mg) 227.1 ± 16.8x 168.3 ± 12.6y 176.67 ± 90.1xy 
CAT Activity (U/mg) 1037.65 ± 102.6x 1087.9 ± 92.1x 1425.7 ± 320.0x 
 
1. Values are expressed as mean ± SE. For GPx and CAT activities N=8 per Zucker 
Obese dietary groups and N=4 for the Zk-LC group.  
2. Values in the same row not sharing a common superscript are significantly different 
(P≤0.05, ANOVA analyses with LSD post hoc tests). 
3. One unit of GPx activity is expressed as the amount f enzyme that would catalyze 
the oxidation of 1.0 nmol NADPH to NADP+ per minute at 25°C. 
4. For catalase activity one unit is defined as the amount of enzyme that will cause 
formation of 1.0 nmol of formaldehyde per minute at 25°C. 
5. Abbreviations: Zk-OBN, Zucker Obese normal vitamin B6 group; Zk-OBH, Zucker 
Obese high vitamin B6 group; Zk-LC, control group –non-injected Zucker Lean rats; 




Study 2 was undertaken to determine if treatment with supplementary pyridoxine would 
reduce obesity-related oxidative stress and thereby suppress colon carcinogenesis. To our 
knowledge, it was the first study to examine the eff ct of supplementary pyridoxine against 
colon carcinogenesis in an obese state. Zucker Obese rat  were fed high B6 two weeks prior 
to carcinogen injection to improve the state of the colon. It was hypothesized that this would 
reduce oxidative stress and inflammation during initiation and thereby suppress 
carcinogenesis. Using ACF as a biomarker, results from the study did show that pyridoxine 
was suppressing the promotion of early colon carcinoge esis. Zucker Obese rats receiving 
high B6 had lower numbers of total, primal and intermediate ACF compared to their normal 
B6 counterparts. Moreover, a high vitamin B6 diet modulated a number of parameters in 
hepatic tissue and plasma, suggesting a favorable effect.   
 
The liver accounts for 10% of the total body pool of PLP and is the primary organ 
responsible for metabolism of B6 vitamers (Merrill et. al., 1984). High concentrations of 
antioxidants and antioxidant enzymes occur within te liver. In addition to plasma, liver 
tissue was used to examine the antioxidant capacity of p ridoxine in an obese animal model. 
The redox state of liver tissue was assessed by evaluating levels of nitric oxide, GSH and 
measuring activities of antioxidant enzymes, SOD, CAT and GPx. There was no effect by 
supplementary vitamin B6 on SOD and CAT in Zucker animals. However, hepatic GSH 
levels increased while GPx activity decreased in Zucker Obese rats receiving supplementary 
vitamin B6. The concentration of GSH has a major effect on its antioxidant function; GSH 
concentrations have been observed to decrease when oxidative stress increases. Furthermore, 
a reduction in GPx activity in the high B6 group may suggest lower oxidative stress. 
Together, these results suggest that high vitamin B6 is exerting a protective effect. 
 
In the present study, nitrite served as a marker for NO.  NO is a highly reactive free radical. 
There is conflicting evidence on the concentrations f NO and its role in carcinogenesis 
(Pervin et. al., 2007). Studies have shown that NO can both promote and inhibit tumor 
progression and metastasis. In general, NO and its derivatives induce oxidative and 
nitrosative stress that causes DNA damage and inhibits activity of DNA repair enzymes 
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(Seifried et. al., 2007). Since the level of nitrite n the colon could not be determined due to 
previous staining with methylene blue, we could not assume its role in the promotion of early 
carcinogenesis. However, the concentration of nitrite in plasma and liver tissue was 
measured. Zucker Obese rats receiving high B6 had reduced production of hepatic nitrite 
compared to the normal B6 group. While not significant, plasma analyzed for NO production 
also indicated lower levels in the high B6 group compared to the normal B6 group. 
Comparing the two obese treatment groups alone, it would appear that supplementary B6 is 
having a protective effect by decreasing NO production and subsequently decreasing the 
opportunity for nitrosative-dependent cellular damage in the liver. In combination with lower 
liver weights, one can suggest that high B6 was ameliorating the state of the organ. The level 
of hepatic nitrite in Zucker Lean rats was higher than quantities measured in both Zucker 
Obese groups. Similar results were found in Zucker L an rats not injected with 
azoxymethane. It could be possible that the large diff rences in NO synthesis between the 
obese and lean groups could be attributed to differences in the phenotypes. Zucker Obese rats 
are susceptible to different physiological stresses that are due to hyperphagia, including 
increased fat accumulation, high glucose, hyperinsuli emia and inflammation. However, 
based on the overall findings in this study and the complexity of the NO signaling network 
and its effects, further experimental analysis on the tissues could be performed to better 
speculate the role of NO at this stage of disease progression and in each phenotype. This 
might include measuring protein expression of NOS isoforms (iNOS and eNOS) in hepatic 
and colon tissue. 
 
Vitamin B6 is a coenzyme of the transulfuration pathway that me abolizes homocysteine, 
generating cysteine. The biosynthesis of GSH is limited by the availability of cysteine. By 
treating Zucker Obese rats with high B6 it was expected that there would be an increase in 
circulating vitamin B6 in plasma and localized in tissues. Increased physiological 
concentrations of vitamin B6 should translate to its greater use as a co-factor for PLP-
dependent enzymes that participate in the transulfuration pathway. In theory, this would 
decrease homocysteine and increase cysteine. The conc ntration of plasma PLP in the Zucker 
Obese high B6 group did not vary significantly from the normal B6 group. High B6 also had 
no affect on the concentrations of plasma homocysteine and cysteine. Previous studies in rats 
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suggest that plasma PLP levels do not provide a repres ntative indication of vitamin B6 status 
(Schaeffer et. al., 1989). Therefore, we can not conclude that systemically, high B6 intake is 
not having an effect on vitamin B6 status. However, the findings do indicate that high vitamin 
B6 is not exerting an effect on carbon-1 metabolism in plasma.  As previously noted GSH 
levels in hepatic tissue of the high B6 group increased. Provided that the liver is the prima y 
organ for vitamin B6 metabolism, we could assume that at a supraphysiological dose more B6 
was localized at this site and available as a coenzyme for GSH synthesis.  
 
White blood cells are increased during inflammation. It appears that supplementary vitamin 
B6 was exerting an effect by lowering concentrations f monocytes and lymphocytes. Given 
the intimate relationship between inflammation and cancer, further research would be 
necessary to determine how vitamin B6 is exerting an effect and the implications. This would 
include analyzing changes in markers for inflammation between the two B6 treatment groups. 
Supplementary vitamin B6 treatment also significantly reduced platelet count. Activation and 
aggregation of platelets are key events in the pathophysiology of thrombosis, atherosclerosis, 
inflammation and cancer (Ginsberg et. al., 1988, Gasic et. al., 1968., Jurasz et. al., 2004). 
Evidence suggests that decreased platelet counts reduce metastasis (Gasic et. al., 1968). 
Cancer cells have been shown to aggregate platelets conferring a selective advantage for 
survival and spread. Tumour-platelet aggregates help tumour cells evade the immune system, 
protect them from the sheer forces of flowing blood, embolize the microvasculature at new 
sites and facilitate adhesion to vascular endothelium (Jurasz et. al., 2004). In addition, 
platelets can secrete growth factors that can be used for tumour cell proliferation (Honn and 
Tang, 1992). Vitamin B6 has been shown to inhibit platelet aggregation and suggested as a 
compound that should be included in the design of novel antiplatelet agents (Chang et. al., 
2002 and Zhang et. al., 2004). Given a reduction of platelet count by supplementary vitamin 
B6, previous evidence of the vitamer’s ability to reduce aggregation and deleterious effects of 
the platelet-tumour relationship, one can suggest that this is a potential mode for 
supplementary pyridoxine’s ability to suppress carcinogenesis.  
 
In addition to evaluating the effect of supplementary vitamin B6 on colon cancer promotion 
and state of oxidative stress, changes in the liverwere also noted. The liver weights of the 
Zucker Obese high B6 group were lower than counterparts receiving normal B6. During 
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termination, visual differences in the pigmentation of the livers between the groups were also 
noted.  In general, livers of the Zucker Lean group and Sprague-Dawley alike present deep 
red livers at termination, reflecting erythrocyte saturation. In contrast, the gross morphology 
of the Zucker Obese liver is observed to be marble-like with yellow coloration; a classic 
indicator of a steatotic liver (Raju and Bird, 2006). At termination, the livers of the high B6 
group appeared darker in pigmentation; a more intense pink/red colour compared to the 
normal B6 group. Changes in liver weight and pigmentation suggest that supplementary 
pyridoxine might be modulating non-alcoholic hepatic steatosis in Zucker Obese rats. Non-
alcoholic steatosis is described as the accumulation of triglycerides within the cytoplasm of 
hepatocytes which often results in impairment of hepatic microcirculation (Ijaz, 2005). In 
vivo studies of animals with steatotic livers have indicated that fatty infiltration reduced total 
hepatic blood flow and hepatic parenchymal microcirculation (Seifalian et. al., 1999 and Ijaz 
et. al., 2005). Studies with Zucker Obese rats have reported an undetected intersinusoidal 
erythrocyte flow compared to control rats (Sato et. al., 1999).While the livers of the high B6 
group did not appear as dark as a Zucker Lean (Fa/Fa) liver, a healthier pigmentation was 
observed. Therefore, one can infer that vitamin B6 is increasing vascular circulation and 
intersinusoidal blood flow in hepatic tissue. The mchanism by which B6 could increase 
hepatic circulation is unclear. However, pyridoxine s a co-factor in a number of important 
metabolic pathways including lipid metabolism, and alteration by greater availability of the 
B6 coenzyme would account for the darker pigmentation. Future investigation including 
histological analysis of hepatic tissue by staining with Oil Red O (ORO) would confirm if 
there were hepatic changes in lipid accumulation.  
 
In addition to lowering liver weight, high B6 reduced plasma cholesterol, another hallmark of 
obesity. High levels of homocysteine, C-reactive protein, triglycerides and cholesterol are all 
strongly associated with cardiovascular disease (LaRos , 1986 and Lin et. al., 2006). While 
supplementary pyridoxine had no effect on plasma homocysteine and triglycerides, this 
finding suggests that high vitamin B6 may be ameliorating the risk of developing 




In conclusion, at a supraphysiological dose, vitamin B6 exerted favorable effects in the 
Zucker Obese animal model. The findings of this study support the contention that an 
abnormal metabolic state which includes obesity and hyperglycemia may increase the need 
for vitamin B6 and that at a high dose it could function as an antioxidant. It is believed that 
continued consumption of supplementary vitamin B6 would decrease tumour incidence by 
not only attenuating oxidative stress, but by also maintaining lower platelet counts and 






General Discussion and Conclusion 
The main objective of this study was to explore if vitamin B6 plays any role in colon 
carcinogenesis.  Epidemiological and experimental studies have supported the notion that 
low B6 status may be causally related to an increased risk for developing colon cancer.   A 
review of the literature regarding the physiological function of vitamin B6, in addition to its 
classical role in amino acid metabolism, suggests that i  plays a role in lipid metabolism and 
also may act as an antioxidant (Kannan and Jain, 2004).  The recommended dose of vitamin 
B6 is based on its classical function involving amino acid metabolism. Vitamin B6 status is 
generally assessed by direct measurement of the level of plasma PLP, total vitamin B6 and 
homocysteine. Whether vitamin B6 functions as antioxidant in vivo remained to be explored.  
In the present research, two studies were conducted.  The first study was conducted in male 
Sprague Dawley rats, using three levels of vitamin B6 (low, normal and high) and two 
different levels of protein (normal and high). We postulated that if indeed vitamin B6 
functions as an antioxidant then a high protein and low B6 diet would increase the oxidative 
stress. Moreover, it was further hypothesized that a low B6 intake would enhance the number 
and growth of early preneoplastic lesions, ACF, while igh B6 would suppress their growth. 
To determine the antioxidant status of the animals a number of measurements were made at 
the plasma and hepatic level. 
 
It was interesting to note that in the high protein and low B6 group the liver weight was 
moderately higher than the other groups and, unexpectedly, the number and growth of ACF 
were lowest in this group.  The results of ACF enumeration did not support the conjecture 
that a low B6 intake would augment the risk of developing colon ca cer. As a matter of fact, 
in the other groups, a similar number of ACF were enumerated regardless of the level of B6 
or protein treatment.  When the dietary variables were scrutinized, it became apparent that 
the level of protein was an important variable. The high protein groups generally exhibited 
lower levels of oxidative stress markers and plasma levels of cholesterol and triglycerides. In 
the high protein groups, the additional protein was added at the expense of an equal amount 
of carbohydrate. One can suggest that, in part, the diff rences noted between the normal and 
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high protein groups were due to the differences in the level of carbohydrate.  Therefore, the 
findings did not support the hypothesis that a low B6 diet would enhance or a high B6 intake 
would reduce the risk of developing colon cancer.   In contrast, our findings suggest that 
preneoplastic lesions need B6 for optimal growth. The low B6 diet in the normal protein 
group did not show any sign of B6 deficiency suggesting that, in order to induce defici ncy, a 
longer duration may be required or the low B6 used in our study may be inducing only a 
border line compromised status.  
 
In the second study, a completely different animal odel was used. We used Zucker Obese 
rats known to be a good model of human obesity. Zucker Obese rats exhibit a number of 
physiological abnormalities including elevated levels of pro-inflammatory cytokines and 
increased oxidative stress. These animals are susceptible to liver steatosis, diabetes and colon 
cancer. It is hypothesized that the reason these animals are highly sensitive to developing 
colon cancer is because they are in a chronic stateof inflammation, a condition known to 
enhance the risk of colon cancer. We wanted to determin  if the sensitivity of these animals 
to colon carcinogenesis could be modified if vitamin B6 intake was increased.  The rational 
for this study was that supplementary vitamin B6 might alleviate the oxidative stress response 
in vivo. It was interesting to note that not only did a high B6 diet reduce the number of ACF, 
but a decrease in a number of physiological parameters were noted compared to the normal 
vitamin B6 group. Zucker Obese rats exhibit liver steatosis and hepatomegaly. In this study, 
liver weights in the high B6 group were significantly lower than their normal B6 counterparts. 
The number of monocytes, platelets and lymphocytes w re also lower in the high B6 group.  
Hepatic GSH level increased in the high B6 group with a concomitant decrease in glutathione 
peroxidase activity compared to the normal B6 group. These findings supported the notion 
that a pharmacological dosage of B6 was beneficial to the obese rats. 
  
The study conducted in the Zucker Obese rats has several limitations.  We were unable to 
collect sufficient blood samples to conduct a complete analysis of oxidative stress markers at 
the plasma level. As a pilot study, the sample sizewas kept small and, as a result, all of the 
colons were stained for crypt enumeration. In the future, the sample size could be increased 
to accommodate the need to investigate levels of oxidative stress and inflammatory markers 
in colon tissue. 
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The two studies differ a great deal from each other; therefore, a direct comparison between 
the findings of the two studies can not be made.  Nvertheless, both studies raise important 
questions. The findings of the second study are intres ing and suggest that in future study, 
the role of vitamin B6 in pre- and post-initiation stages of carcinogenesis must be conducted. 
By increasing the duration of the study period from six to 24 weeks, the effect of 
supplementary vitamin B6 on tumour incidence could be determined.   It is also important to 
determine and establish if vitamin B6 is indeed reducing inflammation or if it has some other 
role when ingested at a dose normally not achievabl by diet.   The effect of high B6 on 
plasma cholesterol and other blood constituents were not expected and warrant further 
investigation.  
 
This research has provided evidence to consider vitamin B6 as a nutraceutical with a potential 






ACF  aberrant crypt foci 
ALT alanine aminotransferase 
AOM azoxymethane 
Apc adenomatous polyposis coli 
AST aspartate aminotransferase 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ATP adenosine 5’-triphosphate 
BSA bovine serum albumin  
CAT catalase 
CBC complete blood count 
CBS cystathionine β-synthase 
Cd cadmium 
CGS cystathionine γ-lyase 
CK creatine kinase 
CE cholesterol esterase 
CO cholesterol oxidase 
Cu copper 
DNA deoxyribonucleic acid 
DTNB 5,5’-dithiobis-2-nitrobenzoic acid 
DTT dithiothreitol 
EDTA ethylenediamine tetraacetic acid 
FAP familial polyposis 
GLDH glutamate dehydrogenase 
GK glycerol kinase 
GOD glucose oxidase 
GPx glutathione peroxidase 
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GR glutathione reductase 
GSH glutathione 
GSSG glutathione disulphide 
H2O2 hydrogen peroxide 
Hb hemoglobin 
HCT  hematocrit  
HDL high density lipoprotein 
HK hexokinase 
HPLC high-performance liquid chromatography 
HPNC hereditary non polyposis colorectal cancer 
HRP horseradish peroxidase 
iNOS inducible nitric oxide synthase 
LDL low density lipoprotein 
LDH Lactate dehydrogenase 
LF low fat 
MCH mean corpuscular hemoglobin  
MCHC mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume  
MDH malate dehydrogenase 
MethylTHF N-5-methyltetrahydrofolate 
MethyleneTHF N-5-methylenetetrahydrofolate 
MPV mean platelet volume 
NAC N-acetylcysteine 
NADPH nicotinamide adenine dinucleotide phosphate 






O2- superoxide anion 
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PLP pyridoxal 5’-phosphate 
PMP pyridoxamine 5’-phosphate 
PN pyridoxine 
PN-HCl pyridoxine hydrochloride 
RBC red blood cell count 
RDW red cell distribution width 
RNS reactive nitrogen species 
ROS reactive oxygen species 
SAH S-adenosyl-homocysteine 
SAM S-adenosyl-methionine 
SOD superoxide dismutase 
SD Sprague-Dawley rats 
THF tetrahydrofolate 
VLDL very low density lipoprotein 
WBC white blood cell count 
Zk-LC Zucker lean rats, control group 
Zk-LN Zucker lean rats, AOM-injected 
Zk-Ob Zucker Obese rats 
Zk-OBH 
Zucker Obese rats, AOM injected, receiving 
35 mg/kg of pyridoxine-hydrochloride 
Zk-OBN 
Zucker Obese rats, AOM injected, receiving 





Table B 1: Composition of AIN-93 G experimental diets in g/Kg for Study 1 - Modified 
with respect to casein and vitamin B6 for Sprague-Dawley rats 
 Normal Protein (20%) High Protein (40%) 
Ingredients Low B6 Nor B6 High B6 Low B6 Nor B6 High B6 
Casein 200 200 200 400 400 400 
L-Cystine 3.0 3.0 3.0 3.0 3.0 3.0 
Corn Starch 417.336 417.336 417.336 214.536 214.536 214.536 
Maltodextrin 132.0 132.0 132.0 132.0 132.0 132.0 
Sucrose 109.74 109.74 109.74 109.74 109.74 109.74 
Corn Oil 50.0 50.0 50 50.0 50.0 50.0 
Cellulose 50.0 50.0 50.0 50.0 50.0 50.0 
Mineral Mix  
AIN-93-G 
35.0 35.0 35.0 35.0 35.0 35.0 
Calcium Carbonate - - - 5.8 5.8 5.8 
Niacin 0.03 0.03 0.03 0.03 0.03 0.03 
Calcium 
Pantothenate 
0.016 0.016 0.016 0.016 0.016 0.016 
Pyridoxine-HCl 0.0035 0.007 0.014 0.0035 0.007 0.014 
Thiamin HCl 0.006 0.006 0.006 0.006 0.006 0.006 
Riboflavin 0.006 0.006 0.006 0.006 0.006 0.006 
Folic Acid 0.002 0.002 0.002 0.002 0.002 0.002 
Biotin 0.0002 0.0002 0.0002 0.0002 0.0002 0.0002 
Vitamin B12  
(0.1% in mannitol) 
0.025 0.025 0.025 0.025 0.025 0.025 
Vitamin A 
Palmitate  
0.008 0.008 0.008 0.008 0.008 0.008 
Vitamin D3, 
cholecalciferol  
0.002 0.002 0.002 0.002 0.002 0.002 
DL-Alpha 
Tocopheryl Acetate  
0.15 0.15 0.15 0.15 0.15 0.15 
Vitamin K, 
phylloquinone 
0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 
TBHQ 
(antioxidant) 
0.014 0.014 0.014 0.014 0.014 0.014 
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Table B 2: Composition of AIN-93 G experimental diets in g/Kg for Study 2 - Modified 
with respect to vitamin B6 for Zucker Obese and Lean rats
a 
Ingredients Zk-OBN Zk-OBH Zk-LN Zk-LC 
Casein 400.0 400.0 400.0 400.0 
L-Cysteine 3.0 3.0 3.0 3.0 
Corn Starch 214.536 214.536 214.536 214.536 
Maltodextrin 132.0 132.0 132.0 132.0 
Sucrose 109.74 109.74 109.74 109.74 
Corn Oil 50.0 50.0 50.0 50.0 
Cellulose 50.0 50.0 50.0 50.0 
Mineral Mix  
AIN-93-G 
35.0 35.0 35.0 35.0 
Calcium 
Carbonate 
5.8 5.8 5.8 5.8 
Niacin 0.03 0.03 0.03 0.03 
Calcium 
Pantothenate 
0.016 0.016 0.016 0.016 
Pyridoxine-HCl 0.007 0.035 0.007 0.007 
Thiamin HCl 0.006 0.006 0.006 0.006 
Riboflavin 0.006 0.006 0.006 0.006 
Folic Acid 0.002 0.002 0.002 0.002 
Biotin 0.0002 0.0002 0.0002 0.0002 
Vitamin B12  
(0.1% in 
mannitol) 
0.025 0.025 0.025 0.025 
Vitamin A 
Palmitate  
0.008 0.008 0.008 0.008 
Vitamin D3, 
cholecalciferol  




0.15 0.15 0.15 0.15 
Vitamin K, 
phylloquinone 
0.0008 0.0008 0.0008 0.0008 
Choline Bitartrate 2.5 2.5 2.5 2.5 
TBHQ 
(antioxidant) 
0.014 0.014 0.014 0.014 
 
aAbbreviations: Zk-OBN, Zucker Obese normal B6 group; Zk-OBH, Zucker Obese high B6
group; Zk-LN, AOM-injected Zucker Lean group receiving normal B6; Zk-LC, control Zucker 





Tables and Figures 
 
Table C1. Weekly mean body weights of AOM-injected male Sprague-Dawley rats during 
eight weeks of intervention with diets varying in protein and vitamin B6
a 
 High Protein Normal Protein 
 Low B6 (g) 
Normal B6 
(g) High B6 (g) Low B6(g) 
Normal B6 
(g) High B6 (g) 
Day 1 342.6±4.6x 319.8±8.5y 333.5±6.8xy 321.4±3.5y 337.0±10.8xy 334.8±8.2xy 
Week 1 391.4±5.3x 368.6±10.8x 377.5±7.4x 373.0±8.1x 390.5±12.4x 389.4±6.6x 
Week 2 423.9±5.4 x 396.8±11.0x 401.5±9.3 x 401.1±9.5 x 422.6±14.2 x 421.1±7.6 x 
Week 3 453.6±6.7x 419.0±12.2y 424.5±11.5xy 425.3±12.0xy 450.4±15.6xy 451.4±8.9xy 
Week 4 479.4±8.0x 454.1±11.0x 455.5±14.0x 454.6±14.7x 491.5±20.6x 479.6±9.9x 
Week 5 503.3 ± 8.6xz 466.8±11.9xy 456.8±12.8y 487.0±16.3yz 504.6±16.5z 504.1±10.5z 
Week 6 530.0±9.8x 483.8±11.4y 497.5±16.8xy 512.4±18.5xy 529.5±19.0x 531.0±13.3x 
Week 7 532.8±19.7xyz 500.1±12.0xz 497.5±18.4z 515.4±18.7xyz 547.1±18.2xy 549.0±13.2y 
Week 8 550.0±14.9x 498.6±11.6y 501.6±18.5y 521.2±20.1xy 549.0±19.1x 551.5±13.4x 
 




Table C 2. Amount of diet consumed weekly by AOM-injected male Sprague-Dawley 
rats during eight weeks of intervention with diets varying in protein and vitamin B6 
 High Protein Normal Protein 
 Low B6 (g) 
Normal B6 




Week 1 1584 1464 1442 1591 1567 1565 
Week 2 1052 931 921 939 979 1009 
Week 3 1501 1289 1278 1357 1357 1393 
Week 4 1518 1296 1329 1363 1339 1404 
Week 5 1510 1289 1354 1333 1404 1406 
Week 6 1514 1298 1195 1396 1429 1422 
Week 7 1530 1280 1314 1377 1427 1453 
Week 8 1585 1312 1406 1351 1475 1444 
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Table C 3. Complete blood count analyses in AOM-injected male Sprague-Dawley rats 
after eight weeks of intervention with diets varying in protein and vitamin B6
a 
 High Protein Normal Protein 
 Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
WBC 
(10^9/L) 
12.9 ±1.2xy 13.5 ± 1.2x 10.3 ± 0.9y 12.7 ± 1.6xy 13.4 ± 1.1xy 12.3 ± 0.6xy 
RBC 
(10^12/L) 
9.0 ±0.1x 9.0±0.1xy 8.5±0.3y 8.8±0.1xy 8.8±0.1xy 9.0±0.1xy 
Hb (g/L) 160.0 ± 1.4x  158.0 ±1.9x 158.8 ±3.9x 156.4 ±1.7x 155.3 ±2.3x 159.3 ±1.8x 
HCT (L/L) 0.48 ± 0.00x 0.49 ± 0.00x 0.48 ± 0.01x 0.49 ± 0.01x 0.48 ± 0.01x 0.49 ± 0.01x 
MCV (fL) 53.8 ± 0.8x 54.0 ± 0.4x 53.6±0.6x 54.9±0.6x 54.3±0.6x 54.5±0.5x 
MCH (pg) 53.8 ± 0.8 54.0 ± 0.4 53.6 ± 0.6 54.9 ±0.6 54.3 ± 0.6 54.5 ±0.5 
RDW (%) 12.7±0.1xy 12.4±0.2x 12.4±0.2x 12.7±0.2xy 13.1±0.3y 12.5±0.1x 
MCHC 
(g/L) 
329.9±1.9x 326.0±2.4xy 330.3±1.9x 323.4±0.9y 327.3±2.3xy 325.1±1.8xy 
Platelet 
(10^9/L) 
884.0±65.0xy 883.3±25.6xy 866.5±38.9x 935.3±38.0xy 1000.3±41.4y 953.1±48.6xy 




















0.26 ± 0.02 0.25 ± 0.03 0.20 ± 0.04 0.23 ± 0.04 0.25 ± 0.04 0.22 ± 0.03 
aAll values are expressed as mean ± SE, N=8 per dietary group. Values in the same row not 
sharing a common superscript (x, y, z) are significantly different (P≤0.05, ANOVA analyses 
with LSD post hoc tests). Abbreviations: WBC, white blood count; RBC, red blood count; 
Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean 
corpuscular hemoglobin; RDW, red cell distribution width; MCHC, mean corpuscular 
hemoglobin concentration; MPV, mean platelet volume.
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Table C4. Complete clinical status of plasma in AOM-injected male Sprague-Dawley rats after 8 weeks of intervention with 
diets varying in protein and vitamin B6
a 
 High Protein Normal Protein 
 Low B6 Normal B6 High B6 Low B6 Normal B6 High B6 
Creatinine (umol/L) 9.1±3.4x 12.9±2.8xy 19.0±3.4y 19.6±4.2xy 11.5±2.7y 13.8±3.2y 
Urea (mmol/L) 5.9±0.2x 5.6±0.2x 5.1±0.3xy 4.6±0.3y 5.1±0.4xy 5.1±0.3xy 
HDL-C (mmol/L) 1.8±0.1xy 1.5±0.1x 1.6±0.2x 1.9±0.2xy 2.0±0.2y 2.0±0.2y 
Cholesterol (mmol/L) 2.2±0.2 xy 1.8±0.1 x 1.9±0.2 x 2.2±0.2 xy 2.4±0.2 y 2.4±0.2 y 
Glucose (mmol/L) 11.2±1.0x 10.6±0.9x 10.6±0.9x 10.4±0.8x 11.5±1.0x 12.0±0.7x 
Triglycerides (mmol/L) 1.4±0.4x 0.8±0.1y 0.8±0.1y 1.4±0.3x 1.2±0.1x 1.7±0.2x 
Total Bilirubin 
(umol/L) 
3.8±0.4 3.3±0.3 3.4±0.4 3.6±0.3 5.6±1.2 3.9±0.3 
Conjugated Bilirubin 
(umol/L) 
1.0±0.0 1.0±0.0 1.1±0.1 1.0±0.0 1.5±0.5 1.0±0.2 
AST (U/L) 103.3±8.2xz 99.6±5.1xz 109.0±4.2x 79.4±5.3y 92.8±5.7z 80.8±4.0y 
ALT (U/L) 47.3±5.3xy 47.0±3.3xy 52.8±4.8x 37.5±3.3y 50.4±6.0x 40.3±3.9xy 
CK (U/L) 157.4±9.5 150.5±10.3 181.8±43.9 143.5±10.5 162.0±14.3 126.5±9.0 
aAll values are expressed as mean ± SE, N=8 per dietary group. Values in the same row not sharing a comm n superscript (x, y, z) are 
significantly different (P≤0.05, ANOVA analyses with LSD post hoc tests). Abbreviations: HDL-C, high density lipoproteins; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase. 
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Table C5. Weekly weights of AOM-injected Zucker Obese and Lean rats and Control 
Zucker Lean rats after dietary treatment with vitamin B6
a 
 Average Weekly Mass (g) 
 Zk-OBN Zk-OBH Zk-LN Zk-LC 
Week 1 358.8 ± 15.7x 383.8 ± 19.8x 194.8 ± 6.5y 189.9 ± 3.2y 
Week 2 435.4 ± 7.1x 448.5 ± 11.6x 217.0 ± 6.7y 208.5 ± 4.1y 
Week 3 470.6 ± 7.6x 485.8 ± 13.3x 228.4 ± 6.8y 225.6 ± 6.2y  
Week 4 488.8 ± 7.6 x 499.8 ± 14.1 x 238.5 ± 7.2 y 236.0 ± 4.4 y 
Week 5 492.6 ± 7.6 x 503.8 ± 15.9 x 241.8 ± 6.9 y 242.3 ± 5.0 y 
Week 6 509.9 ± 7.4 x 526.5 ± 16.9 x 255.9 ± 7.0 y 249.7 ± 5.3 y 
Week 7 526.5 ± 9.5 x 533.1 ± 13.2 x 265.1 ± 7.3 y  258.0 ± 5.5 y 
Week 8 533.6 ± 10.5 x 540.4 ± 11.7 x 268.8 ± 7.4 y 264.0 ± 5.8 y 
Week 9 544.8 ± 13.1 x 559.4 ± 10.9 x 276.3 ± 6.9 y 269.8 ± 6.3 y 
Week 10 550.8 ± 13.5x  557.2 ± 9.8x 267.0 ± 8.4y NA 
 
aAll values are expressed as mean ± SE, N=8 for Zk-OBN, Zk-OBN and Zk-LN and N=8 for 
Zk-LC. Values in the same row not sharing a common superscript (x, y, z) are significantly 
different (P≤0.05, ANOVA analyses with LSD post hoc tests). Abbreviations: Zk-OBN – 
Zucker Obese normal B6 group; Zk-OBH – Zucker Obese high B6 group; Zk-LN – AOM-
injected Zucker Lean rats; Zk-LC – Control group of Zucker lean rats.  
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Table C6. Complete blood count1,2,3 in AOM-injected female Zucker Obese and Lean 
rats after dietary treatment with vitamin B 6 
Parameters Zk-OBN Zk-OBH Zk-LN 
WBC (10^9/L) 7.7 ± 1.1x 5.5 ± 0.8x 5.2 ± 1.0x 
RBC (10^12/L) 9.2 ± 0.2x 9.0 ± 0.2x 8.6 ± 0.1x 
Hb (g/L) 150.3 ± 1.6x 149.1 ± 2.4x NA 
HCT (L/L) 0.45 ± 0.01x 0.45 ± 0.01x 0.43 ± 0.00x 
MCV (fL) 49.0 ± 0.8x 49.4 ± 0.5x 49.3 ± 0.6x 
MCH (pg) 16.4 ± 0.2x 16.8 ± 0.2x 17.3 ± 0.2y 
MCHC (g/L) 336.4 ± 3.0x 334.4 ± 2.1y 341.7 ± 2.2x 
RDW (%) 14.4 ± 0.2x 15.0 ± 0.3x 13.1 ± 0.5y 
Platelets (10^9/L) 975.4 ± 43.3x 833.5 ± 46.8y 800.3 ± 59.4y 
MPV (fL) 7.4 ± 0.2x 7.5 ± 0.1x 5.9 ± 0.9y 
Seg Neutrophil 
(10^9/L) 
2.4 ± 0.3x 2.0 ± 0.3x 1.0 ± 0.2y 
Lymphocyte (10^9/L) 4.7 ± 0.7x 3.0 ± 0.6x 3.9 ± 0.9x 
Monocyte (10^9/L) 0.4 ± 0.1x 0.3 ± 0.0 y 0.1 ± 0.0 y 
Eosinophil (10^9/L) 0.08 ± 0.01 0.09 ± 0.01 0.11 ± 0.02 
 
1. Values are expressed as mean ± SE. N=8 for Zk-OBN and Zk-OBH dietary groups 
and N=6 for Zk-LN. 
2. Values in the same row without a common superscript a e significantly different 
(P<0.05, ANOVA analyses with LSD post hoc tests).  
3. Abbreviations: Zk-OBN, Zucker Obese normal B6 group; Zk-OBH, Zucker Obese 
high B6 group; Zk-LN, AOM-injected Zucker Lean receiving normal B6; WBC, white 
blood cell count; RBC, red blood count; Hb, hemoglobin; HCT, hematocrit; MCV, 
mean corpuscular volume; MCH, mean corpuscular hemoglobin; RDW, red cell 




Table C7. Biochemical status of plasma from AOM-injected female Zucker Obese and 
Lean rats after dietary treatment with vitamin B6
a 
Biochemical 
Parameter Zk-OBN Zk-OBH Zk-LN 
Total Protein (g/L) 80.0 ± 1.7x 76.4 ± 1.4x 75.0±1.3y 
Albumin (g/L) 44.3 ± 2.2x 42.8 ± 1.0x 53.0 ± 1.3y 
Globulin (g/L) 37.6 ± 0.8x 33.6 ± 1.4y 22.8 ± 1.3z 
A:G Ratio 1.1 ± 0.0x 1.2 ± 0.0x 2.4 ± 0.1y 
Urea (mmol/L) 6.7 ± 0.4x 10.3 ± 3.4x 7.4 ± 0.5x 
Glucose (mmol/L) 14.8 ± 0.8x 14.9 ± 1.8x 7.6 ± 0.5y 
Cholesterol (mmol/L) 11.9 ± 0.4x 9.5 ± 1.1y 2.5 ± 0.2z 
Total Bilirubin  
(umol/L) 
3.5 ± 0.3x 6.1 ± 2.8x 2.5 ± 0.2x 
Alkaline Phosphatase 
(U/L) 
313.1 ± 46.0x 237.9 ± 23.6x 184 ± 56.6y 
Triglycerides 
(mmol/L) 
3.5 ± 0.5xy 5.1 ± 1.4y 1.2 ± 0.3x 
CK (umol/L) 562.9 ± 82.1 649.6 ± 118.7 427.7 ± 41.7 
Creatinine (umol/L) 43.9 ± 3.7x 39.1 ± 2.3x 44.8 ± 5.2x 
ALT (U/L) 126.1 ± 35.1x 127.8 ± 19.9x 36.8 ±1.4y 
 
aValues are expressed as mean ± SE. N=8 for Zk-OBN and Zk-OBH dietary groups and N=6 
for Zk-LN. Values in the same row without a common superscript are significantly different 
(P<0.05, ANOVA LSD).  Abbreviations: Zk-OBN, Zucker Obese normal B6 group; Zk-
OBH, Zucker Obese high B6 group; Zk-LN, AOM-injected Zucker Lean group receiving 
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